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ABSTRACT
The inducible expression of different enzymes and transporters involved in the endo- and
xenobiotic metabolism and transport is mainly regulated by three xenosensors: Two
nuclear receptors (NRs), constitutive androstane receptor (CAR) and pregnane X receptor
(PXR), and the bHLH/PAS-family transcription factor aryl hydrocarbon receptor (AhR).
These xenosensors share many ligands, target genes and interaction partners, which
complicates the regulation of endo- and xenobiotic metabolism. Thus, obtaining
clarification  on  the  structure,  ligand  selectivity  and  function  of  the  receptors  is  important
for drug development. Species differences in ligand recognition of the xenosensors
complicate the use of animal models for metabolism studies. In addition, most of the
available  assays  lack  important  proteins  present  in  the  liver  and  thus,  the  results  from in
vitro studies do not necessarily predict the results obtained in vivo. Studies on human CAR
have been especially limited due to the unique properties of the receptor, such as the high
constitutive activity, and the lack of reliable and reproducible assays.
Hepatoma cells are commonly used in drug metabolism studies despite the poor
expression of the key metabolic enzymes, cytochrome P450s (CYPs). In this study, chimeric
constructs of human CAR and PXR were created by adding the activation domain of NFB
to the full length receptors. These chimeric receptors are constitutively active and exhibit
strong target gene activation. The first aim was to study the effect of these chimeric
receptors on CYP expression in hepatoma cells. The receptors were shown to up-regulate
the expression of CYP2B6, 2C9 and 3A4 in both transiently and stably transfected cells. The
generated stable cell lines provide an interesting starting point for further development of
hepatoma cell lines to be used in drug metabolism studies.
The second aim was to develop cell-based xenosensor assays which could complement
other assays to find novel ligands and to study the properties and function of these
receptors. Reporter assays for the three xenosensors were validated and used to screen
various xenosensor ligands and CYP inducers. Novel agonists and inverse agonists,
selective for human CAR over PXR and AhR, were identified. The compounds discovered
were further characterized by different in vitro assays as well as with molecular modelling
techniques. In particular, the agonist FL81 and inverse agonist S07662 can be used as
reference compounds in different assays for human CAR. They could also serve as lead
compounds to develop better CAR ligands for research and therapeutic purposes.
National Library of Medicine Classification: QU 120, QV 36, QV 37.5, QV 38
Medical Subject Headings: Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Xenobiotics; Metabolism;
Drug Agonism; Drug Inverse Agonism; Cytochrome P-450 Enzyme System; Ligands; Gene Expression
Regulation; Biological Assays; Models, Molecular; Cells, Cultured
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TIIVISTELMÄ
Kaksi tumareseptoria, konstitutiivinen androstaanireseptori (CAR) ja pregnaani X reseptori
(PXR), sekä bHLH/PAS-perheeseen kuuluva aryylihiilivetyreseptori (AhR) säätelevät
elimistön omien sekä vierasaineiden indusoituvaa metaboliaa ja kuljetusta. Näillä
vierasainesensoreilla on yhteisiä ligandeja ja kohdegeenejä sekä useita erilaisia
vuorovaikutuksia muiden proteiinien kanssa, minkä vuoksi elimistön omien sekä
vierasaineiden metabolian säätely on monimutkaista. Vierasainesensorien rakenteen,
ligandiselektiivisyyden ja toiminnan selvittäminen on näin ollen tärkeää lääkekehityksen
kannalta. Eläinmallien käyttö metabolian tutkimisessa on haasteellista, sillä vieras-
ainesensoreiden ligandispesifisyydessä on suuria lajienvälisiä eroja. In vitro menetelmillä
saadut tulokset eivät useinkaan korreloi in vivo tulosten kanssa, koska käytetyissä
menetelmissä ei ole mukana kaikkia normaalisti maksassa ilmentyviä tärkeitä tekijöitä.
Erityisesti ihmisen CAR:n tutkimista ovat rajoittaneet reseptorin ominaisuudet, kuten
konstitutiivinen aktiivisuus, ja luotettavien ja toistettavien mittausmenetelmien puute.
Maksan syöpäkudoksesta (hepatooma) eristettyjä soluja käytetään yleisesti lääkeaineen-
vaihdunnan tutkimisessa, mutta ne ilmentävät huonosti tärkeitä sytokromi P450 (CYP) -
entsyymejä. Tässä työssä kehitettiin kimeerisiä ihmisen CAR ja PXR tumareseptoreita
lisäämällä niihin NFB-proteiinin aktivaatioalue. Nämä kimeeriset reseptorit ovat
konstitutiivisesti aktiivisia ja aktivoivat voimakkaasti reseptorien kohdegeenejä. Työn
tavoitteena oli tutkia näiden kimeeristen reseptorien vaikutusta CYP-entsyymien
ilmentymiseen hepatoomasoluissa. Kimeeristen reseptorien osoitettiin lisäävän CYP2B6-,
CYP2C9- ja CYP3A4-entsyymien ilmentymistä sekä transientisti että stabiilisti
transfektoiduissa soluissa. Kehitettyjä stabiileja solumalleja voidaan käyttää apuna
kehitettäessä uusia malleja lääkeainemetabolian tutkimiseen.
Työn toisena tavoitteena oli optimoida solupohjainen aktivaatiomääritys vierasaine-
sensoreille. Näitä uusia määritysmenetelmiä voidaan käyttää yhdessä muiden menetelmien
kanssa etsittäessä uusia ligandeja sekä tutkittaessa reseptorien ominaisuuksia ja toimintaa.
Validoituja vierasainesensorien aktivaatiomäärityksiä käytettiin seulottaessa erilaisia
vierasainesensoreiden ligandeja ja CYP-entsyymien indusoreja. Löydettyjen yhdisteiden
ominaisuuksia tutkittiin tarkemmin erilaisilla in vitro -menetelmillä sekä molekyyli-
mallituksen keinoin. Uutta selektiivistä ihmisen CAR tumareseptorin agonistia FL81 ja
käänteisagonistia S07662 voidaan käyttää referenssiyhdisteinä erilaisissa ihmisen CAR:n
tutkimusmenetelmissä. Löydettyjen ligandien avulla voidaan mahdollisesti myös kehittää
uusia parempia ihmisen CAR:n ligandeja tutkimukseen ja terapeuttisiin tarkoituksiin.
Luokitus:  QU 120, QV 36, QV 37.5, QV 38
Yleinen suomalainen asiasanasto: reseptorit -- tuma; aineenvaihdunta; lääkeaineet; vierasaineet; entsyymit;
sytokromit; ligandit; geeniekspressio; mallintaminen; soluviljely
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1 Introduction
Living organisms are exposed daily to harmful endogenous substances and many
xenobiotics, including drugs, carcinogens, environmental chemicals and pollutants.
Biotransformation reactions are important in the elimination of these foreign and
undesirable  compounds from the body.  The liver,  in  addition to  its  synthetic  functions,  is
the most important xenobiotic metabolizing organ and its multiple functions are carried out
by hepatocytes, which contain a variety of different enzymes and transporters. The
cytochrome P450 (CYP) superfamily consists of a large and diverse group of enzymes
catalyzing the oxidation of endo- and exogenous substances. These are the main enzymes
involved in drug metabolism and their inhibition or induction can have drastic effects on
the pharmacokinetics of drug molecules, often resulting in therapeutic failures or adverse
effects.
The main regulators of xenobiotic metabolism are the aryl hydrocarbon receptor (AhR),
constitutive androstane receptor (CAR) and pregnane X receptor (PXR). These three so-
called xenosensors are ligand-dependent transcription factors (TFs), which control the
inducible expression of their target genes together with coregulator and other accessory
proteins. A large and diverse set of endo- and exogenous ligands can bind to one or several
of these receptors and result in the enhancement or repression of target gene expression.
Certain features of CAR, such as the constitutive activity, distinguish it from other nuclear
receptors. Xenosensors are also involved in various physiological functions, such as cell
cycle regulation, gluconeogenesis, immune response and the metabolism of fatty acids,
cholesterol, bilirubin and bile acids. Many of these functions result from interactions with
other TFs, a process called cross-regulation. Due to these various interaction possibilities,
the regulation of both xenosensor and target gene function is very complex and remains
largely unclear. Studies on the xenosensor function and ligands would be important not
only for drug development, but also for therapeutic uses and novel ligands could provide
new drug candidates for the treatment of serious metabolic disorders.
Several different methods have been developed to study these processes both to
understand the complex network of different proteins and signaling cascades as well as to
clarify the metabolic properties of new chemical entities in the early phases of drug
development. Since animal studies are unreliable due to species specific differences, the
focus has been on the development of in vitro methods using human cells or proteins. These
methods include cell-based methods using primary cells and continuous cell lines, cell-free
metabolic and ligand binding assays as well as computational approaches. An ideal model
for xenobiotic metabolism studies would contain all of the functional proteins involved in
the metabolic processes. However, all of the currently available assays have problems and
limitations and a single assay does not provide information on all the factors and processes
involved in the biotransformation of a compound.
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2.1 XENOBIOTIC METABOLISM
Xenobiotics, such as drugs, poisons and environmental chemicals, are processed and
eliminated in the body via various chemical reactions mediated by different enzymes and
transporter  proteins.  The  metabolism  of  xenobiotics  occurs  in  many  tissues  (e.g. intestine,
lung, kidney and skin), but the primary site of these reactions is the liver. The main goal of
xenobiotic metabolism is to increase the polarity of the mostly lipophilic xenobiotics and
thus, make them more easily excreted. However, these reactions can also activate the
xenobiotics into more reactive and toxic metabolites. The metabolic reactions have
commonly been divided into three Phases (I-III) but this categorization is slightly artificial
because it tells nothing about the order in which these reactions occur. In addition, the term
Phase 0 is sometimes used to describe the uptake of compounds into the cell.
2.1.1 Phase I: Functionalization reactions
Phase I reactions introduce or expose certain functional groups on the metabolized
compound. The reactions can be roughly divided into three different reaction types:
Oxidation,  reduction  and  hydrolysis  reactions.  Within  cells,  most  Phase  I  enzymes  are
located in the endoplasmic reticulum (ER). The hepatic CYP system is the most important
oxidation system and approximately 75-80% of all Phase I reactions are carried out by these
enzymes (Nebert & Russell 2002, Zuber et al. 2002).
Cytochrome P450 enzymes (CYPs). CYP enzymes are heme-containing mono-oxygenases
involved in the oxidative biotransformation of numerous lipid-soluble xenobiotics, such as
drugs, solvents, pesticides and plant products, but they also participate in the metabolism
and synthesis of various endobiotic substances, such as steroid hormones, prostaglandins
as well as bile and fatty acids (Nebert & Russell 2002, Ioannides & Lewis 2004, Denisov et
al. 2005, Wienkers & Heath 2005). CYPs are found in all tissues of the body but the highest
concentrations are present in the liver and intestine. In humans, the enzymes are divided
into different families (18) and subfamilies (44) based on sequence similarity. Altogether 57
CYP genes and 58 pseudogenes have been found (Nelson et al. 2004, Guengerich 2007).
Despite the relatively low sequence similarities between different CYP families, they all
have  a  similar  and  relatively  well-conserved  structure  (CYP-fold),  consisting  of  certain
secondary structural elements (12 -helices (A-L) and 4 antiparallel -sheets), roughly
divided into two domains (Figure 1A.) (Guengerich 2001, Raucy & Allen 2001, Johnson &
Stout 2005, Sirim et al. 2010). The structure is generally very compact but the precise
positioning of the structural elements varies considerably between different CYPs. The
most  structurally  conserved  regions  are  involved  in  the  heme-binding  (Cys  pocket),
whereas  the  most  diverse  part  is  the  substrate-binding region.  Even minor  changes  in  the
amino acid residues in this area have significant effects on substrate binding. The helices F
and  G,  together  with  F/G  and  B/C  loops,  control  the  access  of  substrate  to  the  active  site,
and  their  position,  as  well  as  the  volume  of  the  pocket,  differs  between  individual  CYPs
mirroring the size or dimensions of selective substrates (Williams et al. 2004, Yano et al.
2004, Lewis et al. 2006, Rowland et al. 2006). The heme moiety is essential for the enzyme
3activity and the loss of this group, for example due to inhibitor binding, results in the loss
of enzymatic activity.
CYPs are primarily membrane-associated proteins, located mainly in the ER but also in the
inner membrane of the mitochondria and on the cell  surface (Neve & Ingelman-Sundberg
2010). The amino terminus of the protein anchors the enzyme to the membrane and in most
cases, the active site is exposed on the cytoplasmic side of the ER (Black et al. 1994). CYPs
function as terminal oxidases of an electron transport chain and catalyse a variety of
monooxygenase reactions, including epoxidation, N-, O-and S-dealkylation, deamination,
dehalogenation, N-, P- and S-oxidation as well as aromatic and aliphatic hydroxylation,
depending on the structure of the substrate (Guengerich 2007, Isin & Guengerich 2007). The
basic reaction is the addition of one oxygen atom to the substrate, while the other atom is
reduced to water (Figure 1B.). An essential component for CYP activity is an accessory
nicotinamide adenine dinucleotide phosphate (NADPH) -dependent flavoprotein, which
forms  a  temporary  complex  with  CYP  and  permits  the  flow  of  electrons  to  the  heme
prosthetic group, enabling the oxidation of the substrate (Laursen et al. 2011).
Figure 1. Structure and function of CYP enzymes. A) A schematic  structure of  a CYP enzyme
(CYP-fold) (adapted from Raucy & Allen 2001 and Sirim et al. 2010). The tubes represent -
helices, the arrows -sheets and the grey star heme. The approximate locations of structurally
conserved regions are marked by grey squares. The lengths and sizes of the elements are not
proportional to their actual sizes. B) The catalytic cycle and basic reaction. In short, after the
substrate  binds  the  active  site  of  the  enzyme  and  displaces  the  bound  water  molecules,  an
electron  is  added  by  an  accessory  flavoprotein  NADPH-P450-reductase  and  the  iron  atom  is
reduced from the ferric (Fe3+) to ferrous (Fe2+) state. The binding of the substrate also induces
conformational changes in the active site leading to altered spectral properties. In the following
steps,  a  molecular  oxygen  binds  the  enzyme and  the  adduct  is  reduced  by  a  second  electron
transfer. Further, the resulting group is protonated, leading to the release of a water molecule
and to a reactive intermediate, which removes the hydrogen atom from the substrate and leads
to the generation of the product and its dissociation from the enzyme (adapted from Meunier et
al. 2004).
Approximately  one  fourth  of  all  CYP  enzymes,  mainly  members  of  families  1-3,  are
involved in xenobiotic metabolism. Unlike the CYPs responsible for the metabolism of
endogenous  compounds,  these  enzymes  have  broader  and  overlapping  substrate
specificities  (Guengerich  et  al.  2005).  It  is  estimated  that  over  90%  of  all  drugs  are
4metabolized, at least partially, by different CYPs, the hepatic enzymes being the most
important ones (Table 1.) (Wienkers & Heath 2005, Pelkonen et al. 2008).
CYP1A2 is mainly located in the liver and is involved in the metabolism of planar aromatic
molecules, such as estrogens, caffeine and melatonin, as well as in the bioactivation of
polycyclic aromatic hydrocarbons, aromatic amines and heterocyclic amines, converting
them into toxic or carcinogenic metabolites (Wang & Zhou 2009, Zhou et al. 2010). The
diverse  CYP2  family  is  the  largest  single  group  of  CYPs  in  humans  and  contains  many
important drug metabolizing enzymes. In terms of enzyme amount, CYP2A6 is a minor
form in the liver. It is best known for the coumarin 7-hydroxylation reaction but is also
involved in the metabolism of various small and planar molecules, such as nicotine, and in
the activation of several procarcinogens (Honkakoski and Negishi 1997, Pelkonen et al.
2000, Hukkanen et al. 2005, Di et al. 2009). CYP2B6 has been overlooked perhaps due to its
highly variable expression between individuals and the lack of good model substrates,
inhibitors and antibodies (Wang & Tompkins 2008). It usually metabolizes non-planar,
neutral or weakly basic and highly lipophilic molecules but it also both bioactivates and
detoxifies some precarcinogens (Mo et al. 2009). The CYP2C family consists of four
members (2C8, 2C9, 2C18 and 2C19), together involved in the metabolism of approximately
one-fourth  of  drugs  on  the  market.  CYP2C9  is  the  most  well  known  isoform;  it  is
responsible for the metabolism of relatively small, acidic and lipophilic molecules forming
hydrogen bonds, such as various clinically significant drugs, including warfarin and
ibuprofen (Rettie & Jones 2005, Zhou et al. 2009a). In addition to liver, the highly
polymorphic CYP2D6 enzyme is expressed in many other tissues, and is responsible for the
metabolism of numerous CNS and cardiovascular drugs and some endogenous substrates
mainly via N-dealkylation reactions (Wang et al. 2009, Zhou et al. 2009b). In contrast to
other xenobiotic metabolizing CYPs, CYP2D6 has not been reported to be regulated by any
inducers (Ingelman-Sundberg 2005). Despite its high hepatic expression, CYP2E1 does not
play a significant part in drug metabolism but has a notable role in toxicology, due to its
role  in  the  metabolism  of  many  small  molecules  (e.g. ethanol),  the  production  of  reactive
oxygen species, the bioactivation of industrial solvents, the activation of chemical
carcinogens and acetaminophen-related hepatotoxicity (Caro & Cederbaum 2004, Lu &
Cederbaum 2008, Trafalis et al. 2010).
The most well known and clinically important CYP subfamily is the CYP3A family,
composing of four functional proteins (3A4, 3A5, 3A7 and 3A43) with overlapping catalytic
specificities (deWildt et al. 1999, Burk & Wojnowski 2004, Daly 2006). The CYP3A4 isoform
is the main enzyme in the liver. It participates in the metabolism of various drugs and it is
also involved in the oxidation of endogenous substrates, such as bile acids, and in the
bioactivation of procarcinogens due to its large and flexible active site and a relatively low
degree of substrate specificity (Li et al. 1995, Zhou 2008). It is also susceptible to inhibition
and is highly inducible by a large number of substances. The other CYP3A family members
are minor isoforms in the liver (Daly 2006). The substrate and inhibitor specificities as well
as  inducibility  of  CYP3A5 are  very similar  to  those  of  CYP3A4 but  it  is  only  expressed in
20% of livers mainly due to a splice site mutation. CYP3A7 is predominantly a fetal enzyme
and it has an important role in normal embryonic development and carcinogenesis (Sim et
al. 2005, Leeder et al. 2005). In the adult liver, it is a minor enzyme form and its role in
xenobiotic  metabolism  is  unclear.  The  CYP3A43  is  the  most  recently  discovered  isoform,
which is expressed at low levels in the liver and exhibits a low level of testosterone
hydroxylase activity. Its substrate specificity and involvement in xenobiotic metabolism are
not known (Westlind et al. 2001, Daly 2006).
5The in vivo CYP-mediated metabolism is dependent on the relative amount of different
CYPs in the liver. The expression of most xenobiotic-metabolizing CYPs differs between
individuals and populations due to different genetic and environmental factors.
Furthermore, the regulation of the CYP expression by microRNAs (miRNAs) or epigenetic
mechanisms (Section 2.2.) has been proposed to resolve the so far unexplained
interindividual variation (Ingelman-Sundberg et al. 2007). The genetic factors behind the
inter-individual variation are mainly due to the different polymorphisms of CYPs, resulting
in differences in both expression and function of the enzymes (Table 1.) (Zhou et al. 2009c).
There can be many reasons for the functional CYP polymorphisms, such as gene
duplications, amino acid changes, copy number variation as well as deletions and
mutations creating inactive gene products (Ingelman-Sundberg et al. 2007). Clinically
significant  variations  in  drug  metabolism  are  mainly  caused  by  the  polymorphisms  of
CYP2C9, 2C19, 2D6 and 3A5. The phenotype differences can sometimes also have beneficial
effects for drug therapy. For example, the CYP2C19 phenotype affects the pharmacokinetics
of  proton  pump  inhibitors,  which  can  lead  to  increased  responsiveness  in  poor
metabolizers to treatment of different gastrointestinal disorders (Klotz 2006, Kawamura et
al. 2007).
Other Phase I enzymes. In addition to CYPs, also other enzymes are involved in Phase I
reactions. NAD+ -dependent alcohol and aldehyde dehydrogenases are a group of
isozymes mainly catalyzing the oxidation of alcohols usually to more reactive aldehydes or
ketones and the oxidation of aldehydes to carboxylic acids, respectively (Vasiliou et al.
2004, Edenberg 2007, Garattini et al. 2008). Flavin monooxygenases are a family of five
tissue-specific isozymes with relatively restricted substrate specificities, which catalyze
chemical reactions via the bound flavin cofactor (Cashman 2000). They are NADPH and
oxygen  -dependent  and  mainly  oxidize  compounds  with  nucleophilic  N,  S  or  P  atoms.
Monoamine oxidases are mitochondrial flavoproteins, which catalyze the oxidative
deamination of diverse amines (Edmondson et al. 2004). Epoxide hydrolases add water
molecules to the epoxides, which are often formed in Phase I metabolic reactions and in the
degradation  of  aromatic  compounds,  thus  converting  them  to  dihydrodiols  which  can  be
futher conjugated (Seidegård & Ekström 1997). The majority of xenobiotic epoxides are
hydrolyzed by two enzymes, the microsomal epoxide hydrolase and the soluble epoxide
hydrolase (Arand et al. 2003). In general, the hydration of epoxides leads to more stable and
less reactive products. Finally, the esterases and amidases catalyze the addition of water
molecules to esters or amides (Junge & Krisch 1975).
2.1.2 Phase II: Conjugation reactions
In Phase II reactions, hydrophilic moieties are added to the compound by conjugative
enzymes. Most of the compounds have already been subjected to Phase I reactions but
certain compounds with appropriate groups can be directly conjugated. The most
important conjugation enzymes can be roughly divided into uridine 5’-diphospho-
glucuronosyltransferases (UGTs), sulfotransferases (SULTs), N-acetyl-transferases (NATs)
and glutathione S-transferases (GSTs) (Zamek-Gliszczynski et al. 2006). The UGTs are
localized in the ER and catalyze the conjugation of a glucuronic acid to a substrate molecule
(glucuronidation) (Tukey & Strassburg 2000, Guillemette 2003). These enzymes are
responsible for the metabolism of at least 35% of drugs metabolized by Phase II enzymes.
They are also involved in the metabolism of other xenobiotics as well as many endogenous
compounds, e.g. bilirubin and steroid hormones. SULTs are cytosolic and weakly inducible
enzymes with an overlapping substrate spectrum with UGTs (Gamage et al. 2006, Zamek-
Gliszczynski et al. 2006). Typically, the sulfation reactions predominate at low substrate
concentrations, whereas glucuronidation takes place at high substrate concentrations.
6Although the metabolites from these reactions usually are less toxic than their parent
compounds, occassionally they also produce active and toxic metabolites (Zamek-
Gliszczynski et al. 2006). NATs are responsible for the acetylation of arylamine drugs, such
as isoniazid (Cascorbi 2006, Sim et al. 2008). Glutathione conjugation reactions, catalyzed by
the membrane-bound isoforms of GSTs, are important in drug biotransformation,
especially in the metabolism of electrophiles (Zamek-Gliszczynski et al. 2006). After
conjugation, the highly hydrophilic products are usually excreted in the bile or urine by a
transporter protein (TP).
2.1.3 Phase III: Other modification reactions and excretion
The term Phase III is commonly used to describe the reactions and proteins involved in the
transport of the drug metabolites across different membranes. However, it can also be used
to describe the further processing of the conjugates from Phase II reactions (e.g. Delaforge et
al. 2005).
Although many compounds permeate cell membranes passively, two major groups of TPs,
ATP binding cassette (ABC) transporters and solute carriers (SLC), are involved in the
disposition  of  xenobiotic  compounds  and  their  conjugates  (Giacomini  et  al.  2010).  ABC
transporters are the most important efflux pump proteins, which derive energy from ATP
hydrolysis in order to transport compounds out of cells independently of the substrate
concentration gradient (Chang 2003, Linton & Higgins 2007). The main proteins involved in
the transport of xenobiotics are P-glycoprotein or multidrug resistance protein 1 (P-gp,
MDR1), multidrug resistance associated protein 2 (MRP2) and breast cancer resistance
protein (BCRP) (Chan et al. 2004). The SLCs form a large family of transporters containing
proteins (e.g. organic anion transporting polypeptides, OATPs) which transport their
substrates along the concentration gradient or as secondary active transporters and thus, do
not require ATP (Steffansen et al. 2004, Schlessinger et al. 2010). In contrast to the ABC
transporters, SLCs are mostly responsible for hepatocellular uptake (Phase 0).
2.1.4 Inhibition, induction and adverse effects
Adverse drug reactions (ADRs) are unexpected responses to a given drug and are often
caused  by  inter-individual  differences  in  enzyme  expression  and  activity,  but  can  also  be
due to the absorption, distribution, metabolism and excretion (ADME) or chemical
properties of the pharmaceuticals. Due to the complex regulation of signaling, drug-drug
(or  drug-xenobiotic)  interactions  can take place  at  any level  of  the  ADME process  but  the
most clinically relevant interactions occur primarily in the absorption or metabolism phase.
As  CYPs  are  usually  the  rate-limiting  factors  in  the  metabolic  processes,  they  have  an
important role in many of these adverse effects. The activity of CYP enzymes can be
modulated by external factors via enzyme inhibition, leading to reduced activity, or
induction, which can be defined as an adaptive increase in the expression of the enzyme.
Due to the impact of CYP inhibition and induction in drug therapy, novel drug candidates
are routinely tested for their potential to cause inhibition or induction in the early phases of
drug discovery (Table 1. shows  the  most  commonly  used  probe  substrates,  inducers  and
inhibitors).
Inhibition. The most  common cause  for  adverse  effects  is  the  inhibition of  CYP enzymes,
possibly  leading to  toxic  effects  or  reduced efficacy of  a  drug (prodrugs)  (Bjornsson et  al.
2003, Pelkonen et al. 2008). CYP inhibition can occur at various stages of the catalytic cycle
and  can  be  roughly  divided  into  two  main  types,  reversible  and  mechanism-based
(irreversible) inhibition (Hollenberg 2002, Ortiz de Montellano & Correia 2005, Pelkonen et
al. 2008). Reversible inhibition is more common, for example occurring as direct
competition between the substrate and the inhibitor for a binding site. Mechanism-based
7inhibition requires biotransformation of the inhibitor and occurs either by a reactive
metabolite binding covalently to the enzyme or by formation of metabolite intermediate
complexes and is only terminated by re-synthesis of the enzyme (Ortiz de Montellano &
Correia 2005). The effects of irreversible inhibition in general are considered to be more
serious due to the longer duration as well as the formation of covalent bonds between the
enzyme and inhibitor. This may lead to an autoimmune response triggered by hapten
formation, e.g. the CYP2C9 inhibitor tielinic acid causing fulminant hepatic failure (Lecoeur
et al. 1996). The hydrophobic interactions with the enzyme also play a role in the inhibition
process as can be seen with ketoconazole which, compared to cimetidine, is a more potent
inhibitor of CYP3A4 (Martinez et al. 1999, McGinnity & Riley 2001). Different CYP isoforms
show some degree of inhibitor selectivity. In terms of metabolism, CYP3A4 is the most
prevalent  and important  isoform and is  thus  often involved in  many clinically  significant
ADRs.  Examples  of  CYP3A4  inhibitors  include  some  antifungals  (e.g. ketoconazole,
Greenblatt et al. 2010), macrolide antibiotics (e.g. erythromycin, Zhang et al. 2009), protease
inhibitors (e.g. ritonavir, Sevrioukova & Poulos 2010) and certain dietary compounds (e.g.
bergamottin from grapefruit juice, Lin et al. 2012). Sometimes the inhibition potential of a
compound  can  be  a  useful  property  in  drug  therapy.  One  such  example  is  the  human
immunodeficiency virus (HIV) protease inhibitor ritonavir which enhances the action of
other peptidomimetic HIV protease inhibitors by inhibiting their CYP3A4-mediated
metabolism (Kempf et al. 1997, Zeldin & Pertruscke 2004). The inhibition of conjugation
enzymes (mainly UGTs) and drug transporters (e.g. P-gp) can also lead to adverse effects or
inadequate pharmalogical activity (Grancharov et al. 2001, Balayssac et al. 2005, Beringer &
Slaughter 2005).
Induction. Induction is a protective response against foreign compounds but, in the case of
drug metabolism, it can lead to inadequate therapeutic levels or toxic/ carcinogenic effects
(prodrugs). For example, induction of CYP2E1 can increase the risk or severity of
hepatotoxicity due to the generation of reactive oxygen species and the formation of
reactive metabolites of for example ethanol and acetaminophen (Jaeschke et al. 2002, Liu et
al. 2005). CYP  induction  is  a  slow  regulatory  process  and  usually  occurs in vivo during
continuous use of the inducing compound. Most of the human hepatic CYPs are inducible
(Table 1.)  by  drugs,  dietary  compounds  and  environmental  factors.  The  extent  of  CYP
induction has been shown to vary between individuals, both at the mRNA or protein levels
as well as in terms of the levels of activity, in response to inducers (Lin & Lu 2001). Despite
this variability in the inductive effect, there appears to be a “threshold” above which the
activity cannot be increased (i.e. enzyme  levels  following  maximal  induction  are
quantitatively similar) (Graham & Lake 2008). In contrast to enzyme inhibitors, inducers act
indirectly  and  do  not  require  any  physical  interaction  with  the  induced  enzyme
(Hollenberg 2002). In most cases, the increase of the expression of an enzyme is the result of
an increase in transcription of the gene encoding the enzyme via receptor-mediated
mechanisms (Section 2.2.2) and further, de novo synthesis of the protein, but can also be due
to a decrease in the rate of protein degradation. The best characterized example of such an
inducer is ethanol, which acts by decreasing the degradation rate of CYP2E1 protein
(Roberts et al. 1995).
A typical inducer can induce a wide spectrum of CYPs (Pelkonen et al. 2002). Such well-
known inducers include for example phenobarbital (CYP2A, 2B, 2C and 3A), phenytoin
(CYP2C and 3A), rifampicin (CYP1A, 2A, 2B, 2C and 3A) and carbamazepine (CYP1A2,
2C19 and 3A4) (Dickins 2004, Hewitt et al. 2007). The best known example of a drug-herbal
interaction involves St. John's wort (hyperforin), which induces at least CYP2C19, 2E1 and
3A4 and thus causes decreased plasma concentrations of several drugs (e.g. oral
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contraceptives and warfarin) metabolized by these enzymes (Delgoda & Westlake 2004,
Borelli & Izzo 2009). In addition to the classical view of induction where one compound
causes  induction  affecting  the  metabolism  of  another  compound,  some  drugs e.g.
carbamazepine and artemisinin can induce their own metabolism (autoinduction) by
inducing CYP3A4 and CYP2B6, respectively (Bertilsson et al. 1980, Simonsson et al. 2003).
Even though the ADRs involving the induction of transporters remain to be demonstrated,
some compounds, such as artemisinin (P-gp) and rifampicin (MRP2), have been shown to
increase the expression of these proteins (Payen et al. 2002, Burk et al. 2005).
2.2 REGULATION OF XENOBIOTIC METABOLISM AND TRANSPORT
The expression of a gene can be controlled at multiple levels including transcription,
mRNA splicing and stability, translation as well as post-translational mechanisms such as
protein stability and modifications (Day & Tuite 1998). The most important and most
widely studied mechanism for hepatic CYPs is the transcriptional regulation by various
TFs, such as the so-called xenosensors (AhR, CAR and PXR, Section 2.2.2).
Liver-specific  gene  expression  in  adult  cells  is  controlled  by  at  least  six  families  of  liver-
enriched, albeit not tissue restricted, TFs (Schrem et al. 2002 and 2004). These factors
include several families of hepatocyte nuclear factors (HNFs), the CCAAT/enhancer-
binding proteins (C/EBPs) and the albumin D site-binding protein (DBP), controlling the
expression of different hepatic proteins. The basal expression of hepatic CYP genes is
regulated by at least HNF1, HNF3 and HNF4. HNF4 is known to maintain the
constitutive expression of many hepatic genes, such as enzymes in the subfamilies CYP2
and CYP3A4 as  well  as  different  TPs  and other  nuclear  receptors  (NRs)  (Honkakoski  and
Negishi 2000, Jover et al. 2001, Rodríguez-Antona et al. 2003, Naiki et al. 2004, Kamiyama et
al. 2007). C/EBP is involved in the regulation of at least CYP2 family members (Luc et al.
1996, Jover et al. 1998, Rodríguez-Antona et al. 2003). Together, these and other factors play
critical roles in activating the expression of many hepatic genes and maintaining the hepatic
phenotype of the cells.
Other  mechanisms  are  also  involved  in  the  regulation  of  CYPs  and  the  interindividual
variability  in  expression can,  in  addition to  different  polymorphisms described in Section
2.1.1, be due to genetic changes at the RNA level or due to epigenetic regulation (Ingelman-
Sundberg et al. 2007). Specific RNA-protein interactions in non-coding regions control the
gene expression by either activating mRNA degradation or by preventing ribosomal access
to  the  translation  start  codon.  MicroRNAs  (miRNAs)  are  short  RNA  molecules,  acting  as
post-transcriptional regulators by binding to complementary sequences on target
messenger RNAs (mRNAs) (Bartel 2009). This process usually results in translational
repression or target degradation and thus, gene silencing. The miRNAs regulate numerous
cellular processes such as proliferation, differentiation and apoptosis. The role of miRNAs
in CYP regulation has only been demonstrated for CYP1B1 but also other CYPs containing
a  long  3'-UTR  region  (e.g. CYP1A2, CYP2B6 and CYP3A4) are likely to be regulated by
miRNAs (Tsuchiya et al. 2006, Rodríguez-Antona et al. 2010). Epigenetic regulation refers
to heritable functionally relevant modifications, including DNA methylation and histone
modifications, which change gene expression without altering the nucleotide sequence of
the silenced gene (Rodríguez-Antona et al. 2010). Methylation of gene promoters may
hinder the binding of some transcription factors to their DNA binding sites or alternatively,
the DNA methylation may silence genes by various indirect mechanisms causing changes
in chromatin conformation. So far, the DNA methylation processes have been shown to
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mainly affect CYP1A1, CYP1A2, CYP2C19 and CYP2D6 genes with potentially functional
methylation sites (Rodríguez-Antona et al. 2010). These processes are generally very
flexible  and  the  environment  can  have  a  role  in  the  expression  profile  of  different  CYP
genes.
2.2.1 Xenosensors
The inducible expression of several genes involved in xenobiotic metabolism and transport
is mainly regulated by three so-called xenosensors AhR, CAR and PXR. However, they are
also involved in other regulatory processes in the body, such as homeostasis, cell
differentiation and the metabolism of endogenous compounds. Understanding the
mechanisms of the translocation and activation of these receptors is of interest and, because
of their multiple functions and ligand-dependent activity, they have also become
interesting targets for drug design.
2.2.1.1 Constitutive androstane receptor and pregnane X receptor
Human  (h)CAR  and  (h)PXR  are  two  members  of  the  NR  superfamily  of  TFs.  The  family
consists of 48 receptors which can be divided into different groups based on their function,
ligands or sequence similarities (Aranda & Pascual 2001, Benoit et al. 2004, Bain et al. 2007).
Unlike classical steroid hormone receptors, which bind relatively small and rigid ligands
with high (nM) affinity, PXR and CAR are very nonspecific and bind an exceptionally large
variety of ligands but with low (μM) affinity (Chawla et al. 2001, Willson & Kliewer 2002,
Germain et al. 2006).
Structure. All NRs have a relatively conserved, domain-like structure with different regions
each having a specific function, but also interacting with each other to regulate the overall
receptor function (Figure 2.) (Renaud & Moras 2000, Aranda & Pascual 2001, Benoit et al.
2004, Germain et al. 2006, Bain et al. 2007). The most variable and structurally disorganized
region is the N-terminal domain (A/B), which is able to bind specific coactivators and is
responsible for the ligand-independent activation (activation function 1, AF-1). The region
also contains multiple phosphorylation sites regulating the transcriptional activity of the
receptor (Lavery & McEwan 2005). The DNA-binding domain (DBD, C) is the evolutionary
most  conserved region formed by three  -helices  (H)  separated by zinc  finger  motifs  and
required for DNA binding and receptor dimerization. The hinge region (D) enables the
rotation of the ligand binding domain (LBD) and often contains nuclear localization signals
and phosphorylation sites affecting the transcriptional activity of the receptor. The most
important region for ligand-dependent function is the LBD (E), which is essential for ligand
and coregulator binding as well as for NR dimerization. Commonly, this region consists of
10-13 -helices (H1, H2 etc.) and 2-5 -strands, and is highly conserved in structure, but not
in  sequence.  A  ligand  binding  pocket  (LBP)  is  formed  in  the  middle  of  the  domain  and
sandwiched between two layers of helices. The last C-terminal helix (usually H12, AF-2) is
allosterically controlled by the binding of ligands and forms a site on the receptor surface
for coregulator (Section 2.2.2.3) binding and modifies the effects of the receptor. The C-
terminal part of the receptor (F) is not present in all receptors and its function remains
unknown. In contrast to most other NRs, both PXR and CAR lack the N-terminal (A/B) and
the C-terminal (F) domains (Timsit & Negishi 2007). In addition, the large species-specific
differences in the LBD sequence of CAR and PXR have a substantial impact on the ligand
binding and function of the receptors, thus leading to differences in the responses to
xenobiotics (e.g. Lehmann et al. 1998, Maglich et al. 2003).
The most original feature of hPXR is its large (1280-1544Å3) and flexible LBP, which is about
twice as large as that of hCAR (675Å3) (Watkins et al. 2003a, Xu et al 2004, Timsit & Negishi
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2007). In addition to the seven -helices present in other NRs, the PXR LBD contains
distinct features critical for its specialized function and promiscuity (Watkins et al. 2001,
Watkins et al. 2003b, Chrencik et al. 2005, Ngan et al. 2009). Two additional flexible strands
(1´ and 1) enable the expansion of the pocket to accommodate ligands of various sizes
and shapes. Like the vitamin D receptor (VDR), PXR contains an approximately 60 amino
Figure 2. NR structure. A) A  general  schematic  structure  of  nuclear  receptors  and  the  main
functions of the domains.  Both PXR and CAR lack the N- and C-terminal regions (A/B and F).
NLS = nuclear localization signal B) A 3D representation of human CAR in complex with CITCO
and SRC1 peptide (adapted from Xu et al. 2004). The cylinders represent the -helices H1-H12
(including the 310 helices H2' and H3') and the arrows represent -strands. The ligand binding
pocket (LBP) is shown in dark grey.
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acid region between H1 and H3, creating an extended five-stranded antiparallel -sheet, a
stretch adjacent to the LBP and the H6 is replaced by a flexible loop (Watkins et al. 2001,
Orans et al. 2005). The hydrophobic LBP is formed by 28 mostly non-polar amino acids
with eight polar residues able to form hydrogen bonds with the ligands (Kliewer et al.
2002). The pocket can change both shape and volume and adopt unique conformational
structures depending on the binding ligand and thus allow different ligand binding
configurations.  hCAR  LBD  is  formed  by  11  -helices,  two  310 helices and three -strands
(diMasi et al. 2009). The most unique feature of the receptor is the conformationally rigid
and short H12, which lacks a C-terminal extension and is responsible for ligand-dependent
and independent function of CAR. Furthermore, instead of the extended loop between a
shorter H10 and H12, present in most other NRs, active CAR structures contain an
additional short helix (HX, residues L336, S337, A338 and M339), which is tightly packed
against helices H3 and H10 in the agonist-bound structures and restricts the movement of
H12. The LBP is framed by H2, H3, H4, H5, H6, H7 and H10, and two -strands and
consists of 27 mostly hydrophobic residues (diMasi et al. 2009, Windshügel & Poso 2011).
The polar and potentially charged residues form two regions which might contribute to the
ligand binding, although no direct hydrogen bonding has been observed.
Splicing variants and SNPs. Numerous alternatively spliced hCAR and hPXR mRNAs,
with varying functions and expression patterns, have been detected in different human
tissues (Dotzlaw et al. 1999, Fukuen et al. 2002, Lamba et al. 2004, Lamba et al. 2005, diMasi
et al. 2009). The best studied isoforms of hPXR are PXR.1 (wild type), PXR.2 (111 bp
deletion in exon 5, LBD), PAR-2 (39 additional amino acids at the N-terminal end) and
PXR.3 (123 bp deletion in exon 5, LBD) (Bertilsson et al. 1998, Lamba et al. 2004, Lamba et
al. 2005, Zhou et al. 2009). PXR.2 is the second most abundant transcript in human liver
(approx. 7% of total PXR mRNA, Lamba et al. 2004). Most likely due to the missing portions
of the LBD, the PXR.2 and PXR.3 variants are not able to bind PXR.1 ligands (Lamba et al.
2005). Based on the high prevalence of splice variants with alterations in exon 5, this region
has been thought to be the least conserved of the LBD (Lamba et al. 2005).
The three most studied isoforms of hCAR are CAR.1 (wild type), CAR.2 (SVPT insertion in
exon 7, in the vicinity of the LBP) and CAR.3 (APYLT insertion between exons 8 and 9, in
the ligand binding/heterodimerization domain) (Auerbach et al. 2003, Jinno et al. 2004,
Lamba et al. 2005). CAR.2 and .3 have been shown to be prominently expressed in human
liver and primary hepatocytes (up to 50% of total CAR) (DeKeyser et al. 2011). While the
wild type CAR has high basal activity (see below) in the absence of ligand, both of the
splice variants are ligand-activated, although no variant-specific ligands for CAR.3 have
been found. Di(2-ethyl-hexyl)phthalate (DEHP) has been shown to be a potent specific
activator of CAR.2, while bisphenol A (BPA) is a CAR.1 and CAR.3 agonist but it does not
activate CAR.2 (DeKeyser et al. 2009 and 2011). Other hCAR splicing variants have shown
to result for example from the deletion of exon 7 or exons 10-12, leading to complete loss of
transactivation (Auerbach et al. 2003, Savkur et al. 2003, Arnold et al. 2004, Jinno et al.
2004). The hCAR gene is able to produce many alternative mRNA transcripts and thus,
they are difficult to quantify (Lamba et al. 2005). It has been suggested that these variants
may also account for many of its functional characteristics, such as cellular localization (Li
& Wang 2010).
In addition to splicing variants, numerous SNPs have been identified for hCAR and hPXR
(Lamba et al. 2005, Lamba 2008). As with SNPs in general, different polymorphisms are
concentrated in different populations (e.g. PXR*2 in African-Americans, Zhang et al. 2001)
and have different effects (e.g. PXR*5, which cannot bind DNA, Koyano et al. 2002). Some of
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the SNPs have been shown to affect the basal or induced activity of CYP2B6 and 3A4 in
vitro and hence, it is possible that some of the hCAR and hPXR allelic variants could affect
the expression of their target genes. However, the allelic frequencies of these variants are
very  low  and  their  impact in vivo has not been conclusively proven (Lamba et al. 2005,
Thompson et al. 2005, Lamba 2008, Wyen et al. 2011).
Function. The  simplified  view  on  NR  function  is  that  the  inactive  forms,  residing  in  the
cytoplasm, dissociate from chaperone proteins and translocate into the nucleus after
activation by ligands or other stimuli (Aranda & Pascual 2001) (Figure 4.). In addition, some
receptors are retained in the nucleus bound to unspecific DNA sequences regardless of the
ligand-binding status (Germain et al. 2006). Many NRs, including PXR and CAR, shuttle
between the cytoplasm and nucleus but the details of the mechanisms involved are still
poorly understood. For CAR, it has been suggested that different phosphorylation and
dephosphorylation events, affecting the dissociation of CAR from chaperone proteins, or
cofactors (e.g. glucocorticoid receptor-interacting protein 1, GRIP1) could be involved in the
localization of the receptor (Maruvada et al. 2003, Guo et al. 2006, Timsit & Negishi 2007).
The  dominant  mechanism  of  the  activation  of  PXR  is  the  direct  binding  of  an  agonist
(Moore et al. 2003). In contrast, activation of CAR can happen either by the direct binding of
an agonist or by indirect mechanisms, involving induced nuclear translocation e.g. by
phenobarbital  (PB)  which  is  generally  believed  not  to  bind  to  the  CAR  LBP  (Moore  et  al.
2000, Swales & Negishi 2004, Qatanani & Moore 2005). In cell-based assays, CAR has a high
basal activity, which can be further elevated by agonists or depressed by inverse agonists
(e.g. Forman et al. 1998, Li et al. 2008). The unique structural features (e.g. HX, extended H2,
short H12), different hydrogen bonds and other interactions between various amino acid
side  chains  as  well  as  the  interaction  with  RXR,  all  thought  to  stabilize  the  active
conformation of the receptor, have been suggested to play a role in the constitutive activity
of the receptor (Dussault et al. 2002, Xu et al. 2004, Suino et al. 2004, Windshügel et al.
2007).
In the nucleus, the receptors bind to specific response elements (REs) within their target
gene promoters and, together with various coregulators (Section 2.2.1.3, Figure 4.), alter the
chromatin structure and regulate the expression of these genes. The REs are bipartite
elements with two similar hexamer DNA sequences, called half-sites, separated by one or
more nucleotides (spacer) (Table 2.) (Mangelsdorf & Evans 1995). The sequence and
orientation as well as the spacer and 5'-flanking sequences of the half-sites are important for
NR recognition (Germain et al. 2006). The elements are usually found clustered in the 5'-
flanking promoter region of the NR target gene but also from more distant locations
(Aranda & Pascual 2001, Claessens & Gewirth 2004).
Especially the xenobiotic-response enhancer module (XREM) and phenobarbital responsive
enhancer module (PBREM), which contain several NR-binding elements and are found in
the distal CYP3A4 promoter and CYP2B regulatory regions, respectively, play a major role
in CYP3A4 and CYP2B induction by hPXR and hCAR ligands (Honkakoski et al. 1998,
Goodwin et al. 1999). Both PXR and CAR bind DNA mainly as nonpermissive heterodimers
(i.e. partner ligands cannot activate the complex) with retinoid X receptor (RXR, NR1B),
although PXR has been shown to function also as a homodimer and CAR to bind to DNA
as a monomer (Kliewer et al. 2002, Frank et al. 2003, Noble et al. 2006).
In addition to DMEs and DTs (Table 2.), both PXR and CAR participate in the regulation of
the  metabolism  of  endogenous  substances,  such  as  bilirubin,  bile  acids  and  vitamin  D
(Huang et al. 2003, Xie et al. 2003, Wagner et al. 2005, Hosseinpour et al. 2007). This
happens mainly indirectly by regulation of the expression of genes, such as CYP7A1 and
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Table 2. Response elements, cofactors and regulated genes of human xenosensors.
REsa Known
cofactorsb
Regulated genesc References
CAR
NR1I3
DR4
DR5
ER6
ER8
IR
(AGGTCA)
Coact.
SRC1
SRC2
PGC1
PBP
ASC2
FoxO1
Corepr.
NCoR
SMRT
CYP1A1/2
CYP2B6
CYP2C9
CYP3A4/5/7
ALDH1A4
UGT1A1/6, 2B1
GSTA1/2
SULT1A1/2, 2A1
NAT1
MDR1
MRP2-4
Lee et al. 2007, Yoshinari et al. 2010
Sueyoshi et al. 1999, Wang et al. 2004
Ferguson et al. 2002
Burk et al. 2002, Burk et al. 2004
Maglich et al. 2003
Bock & Köhle 2005, Sugatani et al. 2005
Assenat et al. 2004
Saini et al. 2004, Chen et al. 2007
Westerink & Schoonen 2007a
Burk et al. 2005
Kast et al. 2002, Assem et al. 2004
PXR
NR1I2
DR3
DR4
DR5
ER6
ER8
IR0
PBRE
(AGGTCA)
Coact.
SRC1
SRC2
SRC3
PGC1
NRIP1
FoxO1
Corepr.
NCoR
SMRT
SHP
CYP1A1/2d
CYP2A6
CYP2B6
CYP2C8/9/19
CYP3A4/5/7
ALDH1A4
GSTA1/2
SULT1A1, 2A1
UGT1A1/3/4/6/9
MDR1
MRP2-5
OATPs
Maglich et al. 2002
Itoh et al. 2006
Wang et al. 2003
Gerbal-Chaloin et al. 2002,
Ferguson et al. 2005,
Chen & Goldstein 2009
Lehmann et al. 1998, Pascussi et al. 1999,
Burk et al. 2004
Maglich et al. 2002
Falkner et al. 2001, Maglich et al. 2002
Maglich et al. 2002, Sonoda et al. 2003
Chen et al. 2003,
Gardner-Stephen et al. 2004
Geick et al. 2001
Kast et al. 2002, Teng et al. 2003
Meyer zu Schwabedissen et al. 2008
AhR XRE
(TNGCGTG)
Coact.
ARNT
SRC1
SRC2
CBP/p300
RIP140
Corepr.
AHRR
RIP140
CYP1A1/2
CYP1B1
CYP2S1
NQO1
UGT1As
BCRP
GSTAs
SULTs
Quattrochi et al. 1994, Mandal 2005
Lin et al. 2003
Saarikoski et al. 2005
Yeager et al. 2009
Zhou et al. 2005,
Bock & Bock-Hennig 2010
Tan et al. 2010
Yeager et al. 2009
Yanagiba et al. 2009
aOrientation of half-sites: head-to-tail (direct, DR-n), head-to-head (inverted, IR-n) or tail-to-
tail (everted, ER-n).  Core sequences are shown in brackets and the favoured element in bold
(Kliewer et al. 2002, Honkakoski et al. 2003, Sonoda et al. 2003, Saini et al. 2004, Song et al.
2004, Beischlag et al. 2008). bAHRR=aryl hydrocarbon receptor repressor, ARNT=aryl
hydrocarbon receptor nuclear translocator, ASC2=activating signal cointegrator 2,
CBP/p300=CREB binding protein/E1A binding protein p300, FoxO1=forkhead transcription
receptor 1, NCoR=nuclear receptor corepressor 1, NRIP1=nuclear receptor interaction protein 1,
PBP=peroxisome proliferator-activated receptor-binding protein (TRAP220), PGC-
1=peroxisome proliferator-activated receptor gamma coactivator 1, RIP140=receptor
interacting protein 140, SHP=small heterodimer partner, SMRT=silencing mediator for retinoid
or thyroid-hormone receptors, SRC1-3=nuclear receptor coactivator 1-3 (Synold et al. 2001,
Min et  al.  2002, Shiraki  et  al.  2003, Choi  et  al.  2005, Jia et  al.  2005, Jyrkkärinne et  al.  2005
(CAR); Takeshita et al. 2002, Ourlin et al. 2003, Watkins et al. 2003, Johnson et al. 2006, Li &
Chiang 2005 (PXR); Kumar et al. 1999, Kumar & Perdew 1999, Matthews et al. 2005, Watt et
al.  2005,  Madak-Erdogan  &  Katzenellenbogen  2012  (AhR). cExamples  of  regulated  genes
involved in xenobiotic metabolism, NQO1 = NADPH dehydrogenase quinone 1, dThe regulation
of CYP1A2 is somewhat questionable (Kojima et al. 2007).
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UGT1A1, important for the metabolism or detoxification of these compounds. There are
more recent findings indicating that the receptors are also involved in energy metabolism
either by direct gene regulation or via crosstalk with other transcriptional regulators, such
as the forkhead box proteins O1 (FoxO1) and A2 (FoxA2), involved in gluconeogenesis and
fatty acid oxidation (Kakizaki et al. 2008, Moreau et al. 2008, Wada et al. 2009, Gao & Xie
2010).
Ligands. The ligands of hPXR and hCAR are a miscellaneous group consisting both endo-
and exogenous compounds with different structures and sizes (diMasi et al. 2009).
Examples of compounds binding hPXR include various drugs (e.g. rifampicin, metyrapone,
statins, anticancer compounds and ketoconazole, Harvey et al. 2000, Moore et al. 2000,
Ekins et al. 2007), herbal compounds (e.g. hyperforin  and  certain  compounds  used  in  the
traditional Chinese medicine, Watkins et al. 2003, Mu et al. 2006, Yu et al. 2011), steroid
hormones and metabolites (e.g. progesterone, Kliewer et al. 1998), dietary compounds (e.g.
coumestrol and carotenoids, Rühl et al. 2004, Wang et al. 2008), vitamins (Landes et al.
2003), bile salts and acids (e.g. lithocholic acid, Staudinger et al. 2001, Xie et al. 2001) as well
as various pesticides (Lemaire et al. 2004). The molecular weight, as well as the three-
dimensional shape of a compound, appears to be important if it is to undergo a strong
binding to PXR, despite of the exceptional flexibility of the LBP (Xiao et al. 2011). The first
identified mouse (m)CAR ligands were endogenous androgen metabolites (androstanol
and androstenol), which act as inverse agonists, blocking the constitutive activity of hCAR
at high concentrations (Forman et al. 1998). Other published hCAR inverse agonists include
17-ethinylestradiol (EE2, Mäkinen et al. 2002), clotrimazole (Moore et al. 2002, Auerbach et
al. 2003), meclizine (Huang et al. 2004) and the isoquinoline carboxamide PK11195 (Li et al.
2008), although results on clotrimazole and meclizine are controversial (Mäkinen et al. 2002,
Toell et al. 2002, Lau et al. 2011). Compounds shown to activate (but not necessarily bind
to) hCAR include various drugs (e.g. phenobarbital, phenytoin, artemisinin and statins,
Sueyoshi et al. 1999, Wang et al. 2004, Burk et al. 2005, Kobayashi et al. 2005), synthetic
chemicals (e.g. CITCO, Maglich et al. 2003), environmental chemicals (e.g. nonylphenol,
Hernandez et al. 2009), herbal medicines (e.g. Chinese  herbal  compounds,  Huang  et  al.
2011) and flavonoids (Yao et al. 2010). In addition, hCAR can be activated by high
concentrations of bile acids and bilirubin (Huang et al. 2003, Wagner et al. 2005).
2.2.1.2 Aryl hydrocarbon receptor
AhR is a member of the family of the basic-helix-loop-helix/Per-Arnt-Sim (bHLH/PAS)
transcription  factors.  The  receptor  is  present  in  many  tissues,  such  as  liver,  lung  and
placenta  (Dolwick  et  al.  1993)  and  is  involved  not  only  in  drug  metabolism  and  toxic
responses of chemicals, but also in hematopoiesis (Gasiewicz et al. 2010) and the
differentiation of the lymphoid system (Kiss et al. 2011, Li et al. 2011, Hooper 2011), T-cells
(Quintana et al. 2008), neurons (Akahoshi et al. 2006) and hepatocytes (Walisser et al. 2005).
Structure and variants. Similarly to NRs, AhR has a domain-like structure (Figure 3.). The
N-terminal  bHLH  motif,  formed  by  two  -helices  connected  by  a  loop,  is  responsible  for
DNA binding (basic region, b) and protein-protein interactions (HLH) (Murre et al. 1994,
Whitlock 1999). The N-terminal domain also contains the nuclear localization and nuclear
export  signals  (NLS  and  NES),  required  for  the  shuttling  between  the  cytoplasm  and  the
nucleus (Ikuta et al. 2000). The two PAS domains (A and B) have specific interactions with
other PAS domain containing proteins, such as aryl hydrocarbon receptor nuclear
translocator (ARNT).
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These domains are homologous and highly similar to protein domains originally found in
the Drosophila genes period (Per) and single-minded (Sim). The ligand binding site,
containing  several  residues  critical  for  ligand  binding,  is  located  in  the  PAS-B  domain,
which also defines which dimerization partner can bind the receptor and contributes to the
dimer stability. The C-terminal part of the receptor contains the large transactivation
domain  (TAD),  consisting  of  several  subregions,  which  is  involved  in  coactivator
recruitment and transactivation/repression (Reen et al. 2002, Beischlag et al. 2008). The
subregions are a glutamine-rich region, important for coactivator interactions, the acidic
region and a region rich in Pro/Ser/Thr residues (Kumar & Perdew 1999; Hankinson 2005;
Beischlag et al. 2008). The complexity of these regions is responsible for the various
interactions and thus, the “flexible” transactivation potential of the receptor. The length of
the C-terminus varies between species or even between different strains of laboratory rats
resulting from different stop codon usage (Poland & Glover 1987). A single genetic AhR
variant  seems  to  have  no  or  little  effect  on  CYP1A  inducibility  in  humans,  whereas  a
combination of AhR variants may have significant effects (Harper et al. 2002). However,
such combinations of genotypes are rare and seem to occur primarily in people of African
descent (Wong et al. 2001).
Figure 3. AhR structure. A schematic presentation of AhR structure and the main functions of
the  domains.  NLS  =  nuclear  localization  sequence,  NES  =  nuclear  export  sequence,  bHLH  =
basic  helix-loop-helix  domain,  PAS = Per-ARNT-Sim domain  (A  and  B  repeat  regions),  TAD =
transactivation domain.
Function. Despite the different structure and receptor class, the functional properties of
AhR closely resemble those of NRs (Figure 4.). In the inactive state (no ligand), the receptor
resides in the cytosol, bound to two molecules of heat shock protein 90 (Hsp90), the
immunophilin like X-associated protein 2 (XAP2) and other proteins, such as p23 (Petrulis
and Perdew 2002). Hsp90 and p23 protect the receptor from proteolysis and maintain a
conformation suitable for ligand binding (Cox & Miller 2004). XAP2, interacting with
Hsp90, binds to the NLS sequence, stabilizes the complex and prevents the receptor from
entering the nucleus without a ligand (Petrulis et al. 2000). The ligand binding to the PAS-B
domain induces the dissociation of the chaperone proteins and the exposure of NLS (Ikuta
et al. 2004). The receptor then translocates to the nucleus where it dimerizes with ARNT, in
order to form an active DNA-binding complex, and controls the expression of its target
genes by binding to the xenobiotic response element (XRE) in the regulatory region of these
genes (Denison and Nagy 2003). Another PAS protein, AhR repressor (AHRR), inhibits
both inducible  and constitutive  AhR activity,  by competing with ARNT,  or  by binding to
the XRE (Hahn et al. 2009). Protein kinase C and tyrosine kinase seem to be also involved in
the AhR signal transduction but the mechanisms have been a matter of debate (Backlund &
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Ingelman-Sundberg 2005). Despite differences in receptor sequence or size between
different species, the signalling pathway is highly conserved in all vertebrates as CYP1A
induction is seen in all species (Bank et al. 1992). In addition to the members of the CYP1A
family, AhR regulates numerous other genes, including Phase II enzymes (Table 2.) and is
required for the toxic effects of some important environmental compounds, such as dioxins
(Céspedes et al. 2010).
Ligands. The  AhR  binds  a  wide  variety  of  structurally  diverse  synthetic  and  natural
ligands. The established ligands include the synthetic halogenated aromatic and polycyclic
aromatic hydrocarbons (HAHs and PAHs) as well as natural ligands tetrapyrroles
(bilirubin), flavonoids, tryptophan derivatives and dietary carotinoids (Denison & Nagy
2003). The best example is the CYP1A1 inducing agent, 2,3,7,8-tetrachlorodibenzodioxin
(TCDD), which produces a wide variety of species- and tissue-specific toxic effects (Poland
& Knutson 1982, Mimura & Fujii-Kuriyama 2003). Although various potential candidates,
such as heme degradation products, have been suggested, so far no true endogenous ligand
for human (h)AhR has been found (Denison et al. 2002). Similarly to the NRs, the ligand-
binding affinities of AhR differ between species possibly due to the differences in the amino
acid sequences in the LBDs (Ema et al. 1994).
2.2.1.3 Coregulators
As TFs, in general,  lack the enzymatic activities required for the modulation of chromatin
structure, all three xenosensors either activate or repress target gene expression by binding
either coactivators or corepressors, respectively (Table 2.). Cofactors are a diverse group of
relatively unstable proteins, which lack a distinguishing structural motif possibly due to the
number of different transcriptional steps in which they are involved (Bulynko & O’Malley
2011). Coactivators act as histone acetyltransferases (HATs, e.g. p160 factors) or
methyltransferases or serve as partners for such enzymes and are involved in chromatin
relaxation and thus, the recruitment of the basic transcriptional machinery and activation of
gene expression (Gronemeyer et al. 2004, Bulynko & O’Malley 2011). In contrast,
corepressors recruit histone deacetylases (HDACs) and promote chromatin condensation
and repression of gene expression (Privalsky 2004). Some of the coregulators can also have
mixed effects, depending on the bound receptor. The activity of the receptors and
coregulators can be further controlled by different post-translational modifications, such as
methylation or phosphorylation, which can affect all levels of the NR activation process
(Bulynko & O’Malley 2010).
The recruitment of a certain type of coregulator depends on the NR conformation, or more
specifically, the position of H12, usually determined by the nature of bound ligand (agonist
or antagonist) or the lack of ligand (Privalsky 2004). The recruitment of coregulators is
mainly mediated through special motifs on the surface of NRs (Figure 2.). Interactions with
agonists stabilize the LBD to a conformation, which allows the H12 to form a hydrophobic
cleft together with helices 3 and 4. The so-called charge clamp, holding the conserved
amphiphatic -helical LxxLL motif (NR box), formed by two highly conserved charged
residues (Lys in H3 and Glu in H12) of the LBD, can be found within this cleft (Renaud &
Moras 2000). The binding of a coregulator has also been shown to further stabilize the LBD
structure and the orientation of the bound ligand. In response to antagonists, the
conformation  of  the  LBD  and  the  positioning  of  the  H12  do  not  allow  the  binding  of
coactivators (Privalsky et al. 2004). The H12 can be reoriented from the body of the LBD or
bound to another site outside of the AF2, allowing the corepressors with longer
LxxI/HIxxxI/L motifs to bind to the cleft (Steinmetz et al. 2001). NRs bind different cofactors
depending  on  their  expression  levels  and  the  activity  of  the  receptor  is  dependent  on  the
relative amount of cofactors in the cell (Gronemeyer et al. 2004, Germain et al. 2006).
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In  analogy  to  NRs,  both  AhR  and  ARNT  are  able  to  bind  coregulators  of  various  classes
(Table  2.) but the identity of these factors as well as the mechanisms by which they are
recruited are still poorly understood (Beischlag et al. 2008). The AhR can be inhibited or
downregulated by corepressors (Rushing & Denison 2002, Fallone et al. 2004), by the
binding of AHRR or by degradation (Karchner et al. 2002, Swanson 2002, Mimura & Fujii-
Kuriyama 2003).
Figure 4. Schematic illustration of xenosensor activation and function. Xenosensors are retained
in the cytosol by a multi-protein retention complex, protecting the receptors from proteolysis
and preventing nuclear translocation and the binding of coregulators. After activation by binding
of the ligand (black circle) and/or different phophorylation events (PP2A=protein phosphatase
2A, PKA=protein kinase A), the receptors are released from the chaperone proteins and
translocated to the nucleus. Once in the nucleus, the receptors dimerize with their respective
partners, bind the promoter regions of their target genes (REs) and alter the transcription of
their target genes together with the coregulator proteins, which affect the chromatin structure.
Without ligand, PXR has also been suggested to act as a gene silencer. Modified from diMasi et
al. 2009 and Pavek & Dvorak 2008.
2.2.2 Cross-regulation
Cross-regulation refers to the functional interaction between different signalling pathways,
involving different steps of these pathways or shared components interacting and affecting
both or all of the pathways (Pascussi et al. 2004). NR and AhR signaling pathways are
usually described in a simplified fashion and interactions with other pathways are
neglected (Figure 4.). Cross-regulation can be divided into different levels of action, such as
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sharing of ligands, DNA-binding elements or coregulators, receptor-receptor interactions,
biotransformation of the ligand/activator and secondary modulation via other pathways
(Pascussi et al. 2008).
Due to the xenosensors’ ability to bind various types of ligands, different receptors can
share  ligands,  inducing  either  similar  or  opposite  effects.  An  example  of  such  a  ligand  is
PK11195, which is an hCAR inverse agonist and hPXR agonist (Li et al. 2008). PXR has also
been  shown  to  be  activated  by  liver  X  receptor  (LXR)  and  farnesoid  X  receptor  (FXR)
agonists, such as the synthetic T0901317 and bile acids, respectively (Duniec-Dmuchowski
et al. 2007, diMasi et al. 2009).
Another level of cross-regulation is the sharing of DNA response elements between PXR
and CAR or between xenosensors and other nuclear receptors, leading to the regulation of
the target genes of other receptors by xenosensor ligands. Examples include the DR4
element in the CYP2B6 promoter, shared by CAR and PXR (Mäkinen et al. 2002), as well as
REs  shared  by  PXR/CAR  and  the  vitamin  D  receptor  (VDR,  Drocourt  et  al.  2002)  or  AhR
and estrogen receptor (ER, Ohtake et al. 2003). In general, it appears that some receptors are
able to bind to and transactivate motifs, which are different from their preferred consensus
sequence. However, the binding does not necessarily correlate with the the efficacy of gene
transcription. An RE can also be shielded by a receptor (CAR) by its binding to an
overlapping or adjacent element of another receptor (HNF4) (Miao et al. 2006).
The biological function of the xenosensors depends on the availability of cofactors and the
recruitment of cofactors to another signalling pathway may decrease their availability. The
competition for interaction partners between the three xenosensors (Table  2.) or between
receptors in general might lead to concurrent activation and inhibition of different
pathways (Beischlag et al. 2002, Gurevich et al. 2007). For example, CAR inhibits ER
signalling by reducing the levels of available GRIP1 leading to reduced activity of estrogen
receptor (squelching) (Min et al. 2002). Similarly, the AhR dimerization partner, ARNT, has
been shown to act as a coactivator for the ER, leading to competition between AhR and ER
(Brunnberg et al. 2003). Other TFs can also act as coregulators for xenosensors. For example,
the forkhead transcription factor FoxO1, important for gluconeogenesis, can act as a
coactivator for CAR and PXR (Kodama et al. 2004, Kachaylo et al. 2011). Conversely, CAR
and PXR can act as corepressors of FoxO1 and downregulate the FoxO1-mediated
transcription in the presence of their activators.
The xenosensors can be also regulated by each other or by other TFs or can themselves be a
part of a signalling cascade regulating the expression or function of another receptor. For
example, CAR can be regulated by AhR (Patel et al. 2007). Other examples include the
regulation of CAR by HNF4 together with PGC1 via binding to an RE in CAR promoter
(Ding et al. 2006). Similarly, both PXR and CAR expression is glucocorticoid-dependent in
primary hepatocytes and thus, the activity of the glucocorticoid receptor (GR) is assumed to
influence the expression PXR/CAR target genes (Pascussi et al. 2000, Pascussi et al. 2003). In
addition, cross-regulation may result from the target gene products (enzymes) affecting the
ligands/activators of a receptor controlling another pathway. For example, CAR
participates in the thyroid hormone metabolism by inducing the expression of UGTs and
SULTs, which in turn inactivate thyroid receptor (TR) ligands T3 and T4 (Qatanani et al.
2005). The AhR antagonist, omeprazole-sulfide, is also converted to the AhR activator,
omeprazole, by the PXR target gene CYP3A4 (Gerbal-Chaloin et al. 2006).
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Figure 5. Major factors and variables contributing to interindividual differences in xenobiotic
metabolism. The metabolism of or the induction caused by a compound is affected on different
levels of the xenobiotic metabolism by different physiological and environmental variables,
genetic  variations  of  xenosensors,  DMEs  and  DTs  as  well  as  the  concentration  of  ligands,
inducers/inhibitors and substrates. Modified from Tang et al. 2005.
These  are  only  a  few  examples  highlighting  the  complexity  of  the  networks  involved  in
gene  regulation  by  xenosensors.  In  general,  a  single  xenobiotic  compound  can  initiate  a
very complicated process involving numerous regulatory pathways controlling
homeostasis  of  the  body  and  its  overall  effects  will  depend  on  the  specific  effects  of  the
compound to various receptors, cofactors and enzymes (Figure 5.).
2.3 EXPERIMENTAL TOOLS TO STUDY XENOBIOTIC METABOLISM
(INDUCTION) AND XENOSENSOR FUNCTION
An ideal biological model for xenobiotic metabolism studies should express all the
receptors, cofactors, enzymes and transporters important in the metabolic process, in the
correct proportions. An in vivo system containing all these components would be the most
favourable choice but human studies are considered unethical and animal models are very
often not suitable due to the species specific differences in the responses to xenobiotics. For
example the European Union is tightening the rules to reduce the number of animals being
used in scientific research. Thus, in vitro and in silico studies are increasingly recommended
to study xenobiotic metabolism and to screen novel drug candidates. All of these models or
methods  have  their  own  different  strengths  and  weaknesses  but  in  general  they  are
cheaper, faster and less complex compared to in vivo models.  They  are  also  easier  to  use
and enable the use of human cellular preparations and cell lines. Often, the main aim in the
development  of  these  assays  has  been  to  generate  systems  suitable  for  high  throughput
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screening (HTS) and less emphasis has been placed on the proper validation of the assays
or on the assessment of their limitations (Pelkonen & Turpeinen 2007).
2.3.1 In silico methods
Owing to the increasing knowledge about the structures of xenosensors and CYPs and their
ligands, several computational (in silico)  methods  have  been  developed  to  complement
biological assays, especially for use in the early phases of drug discovery process (Schuster
et al 2006, Ai et al 2009). These methods are intended to reduce the number of molecules
needing to be tested in biological assays but also to study the molecular properties and
interactions of xenosensors or enzymes. However, they have been often unable to provide
accurate predictions on the effects of a compound in vivo, due to the flexibility and
promiscuity of the proteins, the diverse molecular properties of the compounds and the
complexity of ligand-protein interactions (Ekins et al. 2007a,b).
A pharmacophore defines the essential molecular features of a ligand needed for optimal
interactions with a receptor, which then cause the desired biological response (Wermuth et
al. 1998). It can be designed based on the binding site of the target and the active
conformation of the ligands (direct) or by a set of active compounds (indirect), when the
structure  of  the  protein  is  not  known.  In  both cases,  the  ligands have to  be  superimposed
(aligned) (Ekins et al. 2007b, Wolber et al 2008). The features, which are then defined for the
superimposed ligands, are usually various electrostatic and steric properties (hydrophilic
or hydrophobic areas, cationic or anionic groups and hydrogen bond donors/acceptors)
necessary for an optimal interaction between a ligand and a target molecule (van Drie 2003,
Wolber et al. 2008). When the distances between these features are defined, they can be
used to screen different chemical libraries for similar compounds, assumed to exhibit
similar biological activity. This assumption or principle is called the structure-activity
relationship (SAR). Quantitative SARs (QSARs) link the chemical structures to biological
activity with a mathematical expression, which can be used to predict the biological activity
of other chemicals (Wermuth et al. 1998). The quality of a QSAR model depends mainly on
the accuracy of the biological data, the alignment of the compounds used to build the
model and the selection of descriptors, statistical tools and validation of the developed
model. 3D QSAR models are based on the calculation of the force fields around the aligned
ligands and the correlation of the ligands to the field properties (Verma et al. 2010). Various
pharmacophore and 3D-QSAR models have been used to study the active sites of CYP
enzymes and to classify molecules into CYP substrates and inhibitors (Ekins et al. 2001,
Mankowski & Ekins 2003, Li et al. 2008). Even though CYPs have been shown to have many
common structural features, the interactions with substrates and inhibitors differ
significantly. CYP pharmacophore or QSAR models would be useful in drug discovery
(finding of lead structures) and in predicting of ADME properties but, due to different or
inadequate datasets or the different methodologies being used, the predictive power of
these approaches may be questionable (Kurogi & Güner 2001, Shen et al. 2004, Lill 2007).
However, other methodologies based on the ligand's chemical structure, have been shown
to predict the site of metabolism with up to 80% accuracy (Afzelius et al. 2007). Xenosensor
pharmacophores and QSAR-models have been used to study the binding of ligands as well
as the properties of ligands required for specific binding and activation of the receptors.
Several predictive ligand-based AhR QSAR models have been devised to study the hAhR
ligand  binding  affinity  and  the  possible  mechanism  of  toxicity  of  various  ligands  (e.g.
Waller & McKinney 1992, Mekenyan et al. 1996, Lo Piparo et al. 2006, Li et al. 2011, Gu et al.
2012). Due to the huge numbers and structural diversity of the ligands as well as the size
and flexibility of the LBP, there are only a few pharmacophore or QSAR-based studies on
hPXR (e.g. Ekins & Erickson 2002, Schuster & Langer 2005, Dring et al. 2010). In the case of
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hCAR, the lack of known specific agonists has perhaps hindered the use of ligand-based
approaches (e.g. Jyrkkärinne et al. 2003 and 2008, Dring et al. 2010).
In order to obtain a crystal structure of a protein, it has to be produced either in bacterial or
eukaryotic cells, purified and crystallized. The atomic structure is obtained using X-ray
diffraction  and  the  final  model  is  built  based  on  an  interpretation  of  the  electron  density
data (Gouding & Perry 2003, Rupp & Wang 2004, Chayen & Saridakis 2008, Wlodawer et al.
2008). In general, certain structural modifications are needed to improve the water
solubility of CYPs and to enable the crystallization process (e.g. Cosme & Johnson 2000).
Thus, the proteins are subjected to highly unphysiological conditions in the crystallization
procedure. Multiple crystal structures (with or without mutations), with inhibitors or
substrates, exist for human CYPs. The first published human CYP crystal structure was that
of CYP2C9, which became available in 2003 (Williams et al. 2003), followed by structures of
all main hepatic CYPs (Sansen et al. 2007 (CYP1A2), e.g. Yano et al. 2005, DeVore et al. 2011
(CYP2A6), e.g. Gay et al. 2010 (CYP2B6), e.g. Schoch et al. 2004 and 2008 (CYP2C8),
Rowland 2005 (CYP2D6), e.g. Porubsky et al. 2008, Scott & Porubsky 2010 (CYP2E1), e.g.
Yano et al. 2004, Sevrioukova & Poulos 2010 (CYP3A4)). Due to the size and flexibility of
the NRs, the purification and crystallization of an entire receptor is extremely challenging
and thus, only two crystal structures (PPAR and VDR) containing the entire receptor exist
so far (Chandra et al. 2008, Orlov et al. 2011). Otherwise, either LBD crystals, containing a
bound ligand and/or the partner RXR LBD and a cofactor peptide, or DBD structures,
attached to the response element and the partner RXR DBD, exist for these receptors.
Published crystal structures for hCAR and hPXR and their properties are listed in Table 3.
At present, no published crystal structure for AhR is available and the amino acids
important for ligand binding have mainly been studied with the help of the established
homology models as well as through mutation studies (Table 3., Ema et al. 1994, Goryo et
al. 2007). The main problem with the crystal structures is that they are snapshots of a
protein conformation in an unnatural surrounding, and thus, do not necessarily provide
sufficiently detailed information about all of the properties of the protein.
Although the Protein Data Bank (PDB) provides numerous 3D structures for different
proteins, many structures remain uncharacterized (e.g. AhR).  In  homology  modelling,  a
model of the desired protein (target) is created based on sufficient sequence homology (at
least 30-40% identity) of proteins with known structures (templates) (Ginalski 2006, Liu et
al. 2011). Sequence similarity searches are used to find proteins with known high-quality
3D structures and often, multiple template structures are used to build a single model of
the target. In general, flexible structures, such as loops, or insertions and deletions are the
most difficult to predict. The model is built based on the sequence alignment between
template and target. Steric clashes within the model are eliminated by energy minimization
and the model is validated by comparing with the template and by calculating
stereochemical factors (Hillisch et al. 2004, Xiang 2006, Liu et al. 2011). Many homology
models, based on bacterial CYP isoforms and later the first crystallized mammalian enzyme
(rabbit CYP2C5), were created for human CYPs when no crystal structure was available
(Kirton et al. 2002a,b, de Groot et al. 2004). These models have been used to explain and
predict the likely sites of metabolism in a variety of CYP substrates (Hillisch et al. 2004,
Afzelius et al. 2007). Some examples of xenosensor homology models and their applications
are presented in Table 3. The quality and applicability of homology models depend on the
similarity between the template and target.  The evaluation or comparison of the homology
models has been difficult due to the lack of information available or due to different
template structures used (Windshügel et al. 2007). The advantage of homology models is
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that their generation is relatively quick and easy. Nonetheless, homology models tend to
become rather obsolete when a validated crystal structure is available.
Table 3. Crystal structures and examples of homology models of human xenosensors.
Protein Crystal structuresa and homology models References
hCAR Crystal structures (2): LBD (chains B and D) with RXR
heterodimer (chains A and C), SRC1 peptide (chains E-H)
and  agonists  5P  (1XV9)  or  CITCO  (1XVP).  Used  to
determine the binding modes of the two ligands as well as
amino acid side chains important for ligand binding.
Homology models:  Five  models  based  on  PXR  or  ER
alone or both PXR and VDR. Consist of mCAR or hCAR LBD
alone or hCAR LBD with a cofactor (SRC1). Used to study
the ligand binding and binding modes (docking), the key
residues in the LBP, influence of coactivator binding and
the mechanisms of the constitutive activity of CAR.
Xu et al. 2004
Dussault et al. 2002
Xiao et al. 2002
Jacobs et al. 2003
Jyrkkärinne et al. 2005
Windshügel et al. 2005 & 2007
hPXR
hAhR
Crystal structures (8): LBD (chain A) Apo (1ILG) or with
SR12813 (1ILH), hyperforin (1M13), rifampicin (1SKX),
colupulone (2QNV) and PNU-1412721 (3R8D) or the LBD
(chains A and B) with SRC1 peptide (chains C and D) and
SR12813 (1NRL) or with SRC1 peptide (chains C and D,
res. 625-639) and T0901317 (2O9I)
Homology models: Different models based on ER, PXR
crystal structure (apo) (with two SMRT interacting
domains from PPAR/SMRT structure). Used to study the
key residues for ligand and cofactor binding.
Crystal structures (0): No published crystal structures.
Homology models: Different  models  based  on  the
hypoxia-inducible factor 2 (HIF-2) (apo or holo), ARNT
or other PAS domains as well  as ER. Used to study and
compare the ligand binding properties of AhR from
multiple species (e.g. human, mouse and rat) and the
properties of its high-affinity ligands.
Watkins et al. 2001
 Watkins et al. 2003a and b
Chrencik et al. 2005
Xue et al. 2007a and b
Teotico et al. 2008
Cheng & Redinbo 2011
Jacobs et al. 2003
Wang et al. 2006
Jacobs et al. 2003
Pandini et al. 2007
Bisson et al. 2009
Motto et al. 2011
Salzano et al. 2011
aThe number of published crystal structures and their PDB codes are in brackets (PDB
15.12.2011)
Knowledge of the structural features of CYP active sites or the xenosensor LBPs is crucial in
predicting the interactions of a drug and a protein. Both crystal structures and homology
models of human CYPs have produced useful estimates of substrate binding affinities and
in predicting the sites of metabolism in the substrate (Lewis 2002). The crystal structures of
NR LBDs have mainly been used to study the changes in receptor conformation in response
to different ligands and to identify crucial residues or structural elements for ligand
specificity or receptor function (Table 3.). However, the ligand-induced changes in receptor
structure extend outside of the LBD via allosteric interactions between the LBD and DBD.
Thus, the crystal structures of the full length receptors would provide a more accurate view
on the receptor function. Furthermore, the lack of an apo structure has partly hindered
studies on the constitutive activity of CAR (Windshügel & Poso 2011, Jyrkkärinne et al.
2012).
Docking methods predict the energetically most favourable binding orientation of a ligand
and thus, can be used to predict the affinity and activity of the ligand (Taylor et al. 2002).
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The best pose of the ligand is usually selected based on a scoring function (empirical,
knowledge-based or physics-based molecular mechanics force fields), even though their
predictive value is questionable (Huang et al. 2010). Most docking methods suffer from the
fact that the flexibility, a crucial feature for NR function, is omitted or too limited. Different
docking  programs  (e.g. AutoDock,  GOLD)  and  scoring  functions  can  be  used  as  a  part  of
virtual screening approaches and to examine the binding modes and features of different
compounds as well as to obtain information on the protein binding site (Huang et al. 2010,
Meng et al. 2011). Docking methods are often used to predict the binding orientation and
affinity of drug candidates for their target receptors. Docking of a compound into the LBP
or active site usually does not capture the whole picture of transcriptional or other
activation (e.g. allosteric) events. However, docking has been used to visualize the PXR
antagonist ketoconazole binding to the AF-2 regions and not to the LBP (Wang et al. 2007).
These methods have also been used to study the binding of substrates into the CYP active
sites in order to understand the structural basis of enzyme selectivity as well as the specific
interactions between the substrate and different amino acid residues affecting the
orientation of the substrate and thus, their metabolism (Lewis et al. 2006). The sites of
metabolism have also been predicted by using docking methods (e.g. CYP2D6, de Graaf et
al. 2006, Afzelius et al. 2007).
Molecular dynamics (MD) simulations calculate the time-dependent behaviour of a
solvated receptor and ligand system and are able to provide detailed information on the
fluctuations and conformational changes occurring in the protein (Carloni et al. 2002). The
simulations are often used to refine structural models obtained by other methods since they
are especially suited for studying flexible structures, such as loops, within a protein (e.g.
Nurisso et al. 2012). For example, using the MD simulations, it has been shown that the
flexibility of a CYP correlates with their substrate specificity, i.e. 1A2 and 2A6 were the
most rigid and 3A4 most malleable of the enzymes studied (Skopalík et al. 2008,
Hendrychová et al. 2011). The constitutive activity of CAR, the effects of long-range
motions  within  the  PXR  LBD  as  well  as  AhR  ligand  interactions  have  been  studied  with
MD simulations (Windshügel et al. 2005, Teotico et al. 2008, Jogalekar et al. 2010).
2.3.2 Cell-free assays
Cell-free assays are mainly based on either in vitro produced  peptides  or  proteins,  or
proteins isolated from the liver tissue, which can be used to study protein-protein as well as
protein-ligand interactions. These in vitro studies are generally accepted to be used as
supportive and mainly qualitative studies (Brandon et al. 2003).
Metabolic assays. Specifically expressed human recombinant metabolic enzymes or their
genetic variants are commercially available (Supersomes™, Becton Dickinson) and have
been used extensively in early drug development (Bjornsson et al. 2003). In addition to
CYPs,  these  cDNA-derived  enzymes  also  include  UGTs,  FMOs  and  NATs  (Pelkonen  &
Turpeinen 2007). NAPDH-regenerating system or NADPH alone, as well as uridine 5'-
diphospho-glucuronic acid (UDPGA) or 3’-phosphoadenosine-5’-phosphosulfate (PAPS),
are required in these assays as cofactors of CYPs and UGTs or SULTs, respectively. They
are suitable for screening purposes and can be used to study substrate specificities as well
as to generate metabolic products on a small scale (McGinnity & Riley 2001). They can also
be used to study drug-interactions as demonstrated with fluvoxamine-theophylline
interaction (CYP1A2) (Yao et al. 2001).
Liver homogenates, isolated from (pre-treated) animals or humans contain all Phase I and II
enzymes (Brandon et al. 2003). The cytosolic fraction contains soluble Phase II enzymes (e.g.
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NATs,  GSTs,  SULTs  that  require  exogenous  cofactors  for  catalytic  activity)  and  can  be
obtained from a liver homogenate by differential centrifugation. The S9-fraction is a
mixture of human liver microsomes (HLMs) and cytosol separated from the liver
homogenate by low-speed centrifugation and it requires NADPH and other cofactors for
functionality. The S9 fraction has been mainly used in metabolism studies, especially when
primary hepatocytes have not been available, but also in conjunction with the Ames test, to
evaluate the mutagenic potential of compounds and their metabolites (e.g. Hakura et al.
1999). In general, it may provide a more complete metabolic profile but their enzyme
activity is lower than those of HLMs or cytosol. HLMs are derived from the S9 fraction by
differential ultracentrifugation. They are the most widely used in vitro system  for  drug
metabolism, especially in CYP inhibition studies, and they contain CYPs and UGTs but no
cytosolic enzymes (Pelkonen et al. 2005). Thus, they do not fully resemble the physiological
environment.  The inhibition studies  are  usually  carried out  by analysing the  inhibition of
substrate metabolism using specific probe substrates and different analysis techniques,
such as fluorometry or liquid chromatography/mass spectrometry (LC/MS) (Fowler &
Zhang 2008). The activity of HLMs can vary substantially between individuals and thus,
pooled microsomes are often used in experiments (Brandon et al. 2003). Furthermore, it has
to be kept in mind that the results obtained from HLMs are not quantitative estimates of in
vivo biotransformation due to the enrichment of CYPs and UGTs in the microsomes
(Sidelmann et al. 1996). The absence of other enzymes may leave some of the potential in
vivo metabolites unnoticed (Crommentuyn et al. 1998).
In general, subcellular fractions are easy to prepare, use and store. However, they do have
their disadvantages, such as the possible loss of enzyme activity during preparation and the
need for supplemental cofactors. Since the different enzymes and transporters involved in
the  sequential  steps  of  drug  metabolism  and  transport  also  reside  in  different  subcellular
fractions, the entire metabolic process cannot be studied with these systems.
Receptor assays. Different simple and high-throughput in vitro assays, based on the
displacement of a radio-/fluorescently labeled high-affinity ligand by a test compound, can
be  used  to  study  the  binding  of  a  ligand  to  a  receptor  (Raucy  &  Lasker  2010).  In  the
scintillation proximity assay (SPA), the isolated receptors are bound to a bead and
incubated with a test compound and a high-affinity radiolabeled ligand (Figure 6A.). The
binding of nonradioactive ligands can be measured by their ability to compete with the
radioligand (Wu & Liu 2005, Glickman et al. 2008). The assay is generally very flexible due
to the ease of the adjustment of all the components and does not require separation of the
bound from the free radioligand. A less direct approach is the coactivator receptor ligand
assay (CARLA),  in  which the  binding of  an agonist  results  in  a  conformational  change in
the receptor, permitting an interaction with a radiolabeled coactivator protein, and the
interaction can be measured by co-precipitation of the coactivator with the receptor of
interest (pull-down assay, Figure 6B.) (Krey et al. 1997, Kliewer et al. 2002). Compared to
SPA,  CARLA  is  more  labour-intensive  but  has  the  advantage  of  not  requiring  a  high-
affinity radiolabeled ligand. Fluorescence polarization (FP) employs a fluorescently labeled
molecule such as a coregulator peptide (Figure 6C.) (Parker et al. 2000). The technique can
be used to  analyze the  interaction of  two proteins  in  solution.  Time-resolved fluorescence
resonance energy transfer (TR-FRET) is a nonradioactive, homogenous proximity assay,
which uses the transfer of energy between two fluorescent probes as well as the
phenomenon of time-resolved fluorescence (Figure 6D.) (D'Souza et al. 2008, van Royen et
al. 2009). The method has been used to study the interaction of coregulators and NRs
labeled with different fluorophores. The Amplified Luminescent Proximity Homogenous
Assay, or AlphaScreen, is a relatively new, sensitive and easy-to-use technology which has
been applied in NR coregulator recruitment assays (Figure 6E.) (Rouleau et al. 2003). The
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NR and coregulator are coupled to donor and acceptor beads. Upon excitation, the donor
bead releases a singlet oxygen which will cause a luminescent signal to be released from the
acceptor bead. Compared to TR-FRET, AlphaScreen has better sensitivity and a broader
dynamic range (Glickman et al. 2002). In addition, it has been shown to be a very sensitive,
versatile and robust to efficiently screen NR modulators (Rouleau et al. 2003).
Figure 6. Principles of ligand-binding assays. A) SPA:  The  LBD  of  a  receptor  (light  grey)  is
affixed  to  a  scintillant-containing  bead  and  incubated  with  a  radioligand  (square).  A  bound
radioligand is in close enough promixity to the bead and thus stimulates the scintillant in the
bead to emit light, whereas the unbound radioligand or bound non-radioactive test ligand does
not. B) CARLA:  A  GST  fusion  protein  of  the  receptor  is  bound  to  glutathione  beads  and  the
labeled coregulator is added together with the test compound. The protein-protein interaction is
analyzed by SDS-PAGE. C) FP:  Protein  bound  fluorescent  molecules,  excited  with  a  plane-
polarized light, emit light into a fixed plane (polarized light) whereas unbound molecules emit
light  into  a  different  plane  due  to  faster  rotation  during  excitation  (depolarized  light).  The
interaction between the protein and ligand can be evaluated by monitoring the change in
polarization value. D) TR-FRET:  The  coregulator  peptide  and  NR are  labeled  with  donor  and
acceptor fluorophores, respectively. Energy transfer to the acceptor fluorophore occurs upon
excitation of the donor fluorophore, when they are in sufficient proximity (bound) and the
emission from the acceptor fluorophore can be detected in a time-resolved manner. The level of
light emitted is proportional to the degree of the donor-acceptor complex formation. E) Alpha
Screen: The hydrogel coated donor and acceptor beads are brought into close proximity by the
interaction between two attached molecules. A singlet oxygen, converted by the donor bead
upon excitation, reacts with the chemiluminescer in the acceptor bead, resulting in an activation
of fluorophores in the same bead.
PXR assays are probably the most commonly and successfully used in vitro receptor-ligand
binding assays mainly due to the simplicity of the ligand-based activation of the receptor
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(e.g. Jones et al. 2000, Moore et al. 2000, Shukla et al. 2009). In contrast, due to the unique
activation of CAR, ligand-binding assays are of only limited value in identifying CAR
activators and, although sometimes used, the compounds identified by these methods have
often proved to be poor inducers of CYP2B6 expression in human primary hepatocytes
(HPHs) (Moore et al. 2000, Maglich et al. 2003, Li & Wang 2010). Some studies on AhR
ligand affinities and mutations have been conducted using these assays (Delescluse et al.
2000, Backlund & Ingelman-Sundberg 2004). The problem with competition assays using
TCDD is that weak ligands may not be able to compete for the binding to the receptor.
While highly usable, these cell-free methods can produce false positive or negative results
depending on the type of chemical tested. For example, compounds requiring active
transport may never reach the receptor in vivo and thus, receptor-ligand binding assays can
lead  to  false  positives.  A  similar  effect  may  be  seen  if  the  ligand  binding  does  not  evoke
appropriate recruitment of coregulators and thus, a comparable response in vivo (e.g.
paclitaxel and docetaxel with PXR) (Zhu et al. 2004, Harmsen et al. 2007).
2.3.3 Xenosensor transactivation assays
Different transactivation assays, such as cell-based reporter assays, are routinely used to
study the receptor-mediated effects on gene transcription to screen NR and AhR ligands
and to predict the CYP induction resulting from the activation of the receptor (Moore &
Kliewer 2000, Kliewer et al. 2002, Zhu et al. 2004). Most often, the receptor cDNA, the NR-
responsive reporter gene and a transfection control (e.g. -galactosidase) are co-transfected
transiently into a chosen cell line after which the cells are treated with selected test
chemicals (Sinz et al. 2008, Raucy & Lasker, 2010). Due to the increased expression of the
reporter in response to the ligand-receptor interaction, the extent of the receptor activation
can be measured as an increased reporter activity (Figure 7.). A good reporter gene should
be sensitive  and easily  measured and it  should not  affect  the  normal  function of  the  cells.
Commonly used reporter genes include luciferase (LUC), chloramphenicol acetyl-
transferase (CAT) or secreted placental alkaline phosphatase (SEAP) (Schenborn &
Groskreutz, 1999).
The receptor construct can include either a full-length or so-called chimeric receptor, in
which the DBD of the NR has been replaced e.g. by yeast GAL4-DBD (1-hybrid assay)
(Moore & Kliewer 2000, Kliewer et al. 2002). The main benefit of chimeric receptors is the
common GAL4-driven reporter, which can be used for all receptors without prior
knowledge of the DNA-binding properties or optimal response elements for each receptor.
For full-length receptors, reporter constructs with natural CYP3A4 and CYP2B6 promoters
have been used (Moore et al. 2000). Even though most continuous cell lines do not express
significant levels of CAR and PXR, the effects of endogenous NRs on the expression levels
of the reporter with natural promoter cannot be completely ruled out (Goodwin et al. 1999,
El-Sankary et al. 2001). The full-length receptor requires either endogenous or a co-
transfected dimerization partner (RXR) for normal function. Both assay types require
endogenous coregulators to initiate transcription. The development of hCAR-based assays
has  been  more  difficult  due  to  the  high  basal  activity  of  the  receptor,  its  spontaneous
translocation to the nucleus in continuous cell lines and the suggested dual mechanism of
activation (Li et al. 2009). Thus, transactivation assays are often complemented with nuclear
translocation assays. Assays utilizing the newly discovered hCAR variant (CAR.3) have
been  found  to  be  able  to  identify  potential  hCAR  activators  more  easily  due  to  the  lower
basal activity of the receptor (Auerbach et al. 2005, Faucette et al. 2007). AhR is
endogenously expressed in most hepatic cell lines and AhR-activating chemicals have been
mainly studied with the very sensitive chemically-activated luciferase expression (CALUX)
assay (Murk et al. 1996, He et al. 2011). The system is based on stable transfection of a
luciferase reporter, with TCDD-responsive CYP1A1 elements, into a hepatoma cell line
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(Yueh et al. 2005). Examples of different xenosensor reporter assays are shown in Table 10.
(Section 5.2.1).
Figure 7. Principles of different NR transactivation assays. A) M1H: The produced two-domain
(GAL4-NRLBD) fusion protein controls  the expression of  the reporter  gene in response to test
compounds. B) M2H:  Two  produced  fusion  proteins  (GAL4-cofactor  and  NRLBD-AD)  interact
with each other in response to the binding of the ligand to NR LBD and control the expression
the reporter gene.
Mammalian  or  yeast  2-hybrid  assays  (M2H  or  Y2H)  have  been  used  to  study  the
interactions between coregulators and NRs (Fields & Song 1989, Gietz et al. 1997). The use
of  yeast  cells  is  perhaps  more  straightforward  due  to  the  lack  of  endogenous  NRs  and
coregulators, avoiding any competing interactions, but suffers from restricted compound
permeability (Khazak et al. 2005). M2H assays use a coregulator, containing the NR
interaction motifs,  fused with yeast GAL4 DBD and the NR LBD fused with an activation
domain (AD) of a strong transcriptional activator. These two constructs are co-transfected
into  the  chosen  mammalian  cell  and  assayed  to  evaluate  the  interaction  with  a  reporter
construct.  The  binding  of  an  agonist  induces  a  conformational  change  in  the  NR  LBD,
resulting in the recruitment of the interacting cofactor peptide. Since no transcription of the
reporter gene occurs unless the receptor and the coregulator protein interact, this assay
allows detailed studies on ligand-dependent interactions between the receptor-coregulator
pair.
The main problem with transient transfections is the variation in the transfection efficiency
and  thus,  in  the  activation  response.  Stable  lines,  such  as  DPX2  for  hPXR,  have  been
developed to overcome these problems (Trubetskoy et al. 2005, Lemaire et al. 2007).
Another option to streamline the procedure is to freeze a batch of transiently transfected
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cells,  which  have  been  shown  to  produce  similar  results  as  the  unfrozen  cells  (Zhu  et  al.
2007). The choice of the host cell line and culture conditions are generally important since it
has an impact on the magnitude of the induction response (Goodwin et al. 1999). For
example, differences in culture conditions are known to give different responses even with
the established PXR ligands (over 10-fold difference in activation with rifampicin) (Stanley
et al. 2006). In general, transactivation assays are useful for rapid screening of potential
xenosensor activators. However, the overexpression of NRs and high ligand concentrations
used create unphysiological conditions and the impact of the compounds on CYP activity in
vivo cannot be directly predicted. Nonetheless, at least the PXR transactivation has been
shown to correlate well with CYP3A4 mRNA levels and enzyme activity (Luo et al. 2002,
Luo et al. 2004). Similarly to ligand binding assays, these techniques only assess the
activation of one receptor at a time and the effects of crosstalk are not assessed (Wang &
LeCluyse 2003). However, they are preferred over the in vitro ligand-binding  assays  to
screen new chemical entities due to the better correlation with in vivo data and fewer false
positives.
2.3.4 Hepatic cell models
The  liver,  together  with  pancreas  are  crucial  in  controlling  the  metabolism  and  structural
modification of many compounds e.g. digested nutrients, hormones and exogenous
compounds (Zaret & Grompe 2008). Structurally, the liver is formed by lobules, which are
hexagonal structures consisting of the central vein surrounded by sheets of parenchymal
hepatocytes and have a complicated blood circulation system (Turner et al. 2011). The
lobuli are responsible for the majority of liver-specific functions. As the liver is the main site
of the biotransformation of xenobiotics, hepatic in vitro models are of considerable interest.
Hepatocytes are highly differentiated and polarized cells and their functional properties are
at least partly dependent on their location within the lobules. The normal function of
hepatocytes is greatly affected by the liver architecture and the communication between
hepatocytes and non-parenchymal cells. The liver can regenerate after many insults or
injuries by activating the mitosis of mature hepatocytes, meaning that these cells possess a
stem-cell like regenerative capacity (Zaret & Grompe 2008). Despite this extensive
regenerative capacity, it has proven difficult to grow and expand hepatocytes or to
maintain their differentiation state in culture. The common problem with all hepatic cell
lines  is  the  need  for  cell-cell  or  cell-matrix  contacts  or  the  requirement  for  special  growth
factors and other media components for their differentiated function.
2.3.4.1 Human primary hepatocytes
Isolated human primary hepatocytes (HPHs) are used extensively as an in vitro model not
only  in  metabolism  studies  but  also  to  study  the  physiology  and  metabolism  in  the  liver.
Due to their resemblance to hepatocytes in vivo and their well-characterized properties,
they are considered to be the golden standard and are an FDA and EMA -approved method
for drug metabolism and interaction studies (LeCluyse et al. 2005, Gómez-Lechón et al.
2007, Hewitt et al. 2007, EMA Guideline on the Investigation of Drug Interactions 2010 –
29.6.2012, USFDA Draft Guidance for Industry 2012 – 6.4.2012).
The isolation of viable HPHs is a slow and difficult process, which often causes cellular
damage (Li 2007). Mixtures of hepatocytes from different donors have been used to
overcome the large variability in the CYP expression and inducibility between different cell
lots. This variability can result from genetic variations or simply from the age, gender and
prior chemical exposure or illness of the donor as well as the source of the cells (surplus
tissues) (Gómez-Lechón et al. 2007, Figure 5.). After isolation, the cells can be maintained
and used in  suspension for  a  few hours  or  as  monolayer  cultures  for  up to  several  weeks
(Elaut et al. 2006). However, cultured hepatocytes do not proliferate and show a loss of
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liver-specific functions, such as a rapid and uneven decline of CYP expression and activity,
over time (Gómez-Lechón et al. 2007). Supporting the cell-cell interactions, along with
adequate culture media and appropriate 3D structure of the culture, are important for
prolonging cell survival and for maintaining their differentiation state (Section 2.3.6).
Due to the limited supply of fresh hepatocytes, different cryopreservation techniques have
been developed for the long-term storage of these cells. The established techniques have
provided viable hepatocytes with inducible CYP enzymes, which can produce qualitatively
similar results as freshly isolated hepatocytes (Schehrer et al. 2000, Roymans et al. 2005,
Chu et al. 2009). The advantages of cryopreservation are that experiments can be planned in
advance and repeated experiments can be conducted with cells from the same donor in
order to minimize the variation between responses. Cryopreserved cells are also approved
for metabolism and induction studies by the FDA and EMA. Fetal hepatocytes proliferate
in  culture  but  the  regulation  of  CYPs  and  the  general  CYP  profiles  differ  from  adult
hepatocytes. For example, these cells show only marginal PXR-dependent induction and
express high amounts of CYP3A7 (Pelkonen et al. 2008).
2.3.4.2 Continuous hepatic cell lines
Various continuous hepatic cell lines have been used in the early ADME studies due to
their  better  availability  and  ease  of  culturing  compared  to  HPHs.  However,  even  though
some liver-specific functions are retained, the unstable genome and strongly altered
phenotype of hepatic cell lines limit their use in drug metabolism studies.
Tumour-derived cells. Hepatomas, also known as hepatocellular carcinomas (HCC), and
hepatoblastomas  are  two  types  of  primary  liver  cancers.  Cells  derived  from  both  tumour
types are commonly referred to as hepatoma cell lines, regardless of their origin (Donato et
al. 2008). Most hepatoma cell lines have maintained certain properties of normal
hepatocytes, such as the ability to secrete albumin. For drug metabolism studies, the main
problem  has  been  the  low  or  non-existing  expression  and  inducibility  of  CYPs  or  other
DMEs and DTs. This is thought to be mainly due to a decrease in transcription rather than
impaired CYP enzymatic function (Donato et al. 2008). In addition, the former property has
been thought to be due to the lower expression or activity of the key regulators, such as
HNFs, C/EBPs, CAR and PXR or their coregulators (Martinez-Jimenez et al. 2006, Benet et
al. 2010).
The xenosensor and CYP expression profiles of the most commonly used hepatoma cell
lines are shown in Table 4. The HepG2 cell line is the most widely used hepatoma cell line
even though the expression and activity of the major CYPs, as well as UGTs, are lower (0.1-
10% mRNA expression) than in HPHs (Rodríguez-Antona et al. 2002, Westerink &
Schoonen 2007a,b, Hariparsad et al. 2008). The relatively new cell line, HepaRG, has
notably higher CYP expression and activity levels than the other hepatoma cell lines, but
requires a relatively long differentiation period (Aninat et al. 2006, Guillouzo et al. 2007).
For many of these cell lines, the level of CYP activity depends on the origin of the cells,
culture conditions, growth status and possibly also on clonal selection in different
laboratories (Hewitt & Hewitt 2004). Another problem is the heterogeneity and/or different
subtypes present in the culture (Rencurel et al. 2005, Kanebratt & Andersson 2008a,b). For
example, subtypes of HepG2 have been enriched and several cell lines appear to exhibit
higher CYP induction potentials (e.g. WGA, Rencurel et al. 2005). HepaRG also tends to
present two cell types at confluency: Cholangiocytes and hepatocytes. After culturing with
2% DMSO and 50 μM hydrocortisone hemisuccinate, the hepatocytes make up
approximately 50% of the total cell population and form structures resembling bile
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canaliculi (Cerec et al. 2007). Due to this heterogeneity, the extrapolations to in vivo hepatic
induction are not clear because the contributions from the other cell subtypes in the
hepatoma culture is not known.
Despite these problems and weaknesses, hepatoma cell lines are being used in DM studies
as well as in some clinical applications (Donato et al. 2008). With the exception of the
HepaRG line, they are not suitable for direct in vivo comparisons. However, they can
provide useful information on the metabolism and possible toxicity of new chemical
entities in the early drug discovery process. Most of these cell lines express AhR and ARNT
endogenously and thus can be used for assessing ethoxyresorufin-O-deethylase (EROD)
activity or quantitative RT-PCR assays of CYP1A1 but not the predominant CYP1A
isoform, CYP1A2 (Hewitt & Hewitt 2004, Westerink & Schoonen 2007b).
Immortalized cells. Replicative  senescence  is  a  phenomenon  by  which  cells  lose  their
ability to divide and thus remain in the G1 phase of the cell cycle (Cascio 2001, O'Hare et al.
2001). Shortening of telomeres (the repetitive end sequences of eukaryotic chromosomes) in
humans induces senescence and is thought to prevent genomic instability (Cascio 2001). In
most eukaryotic organisms, telomerases (ribonucleo-proteins maintaining telomere ends)
are active only in stem cells, germ cells and in certain white blood cells (Hahn & Meyerson
2001).
The choice of the immortalization method depends on the properties of the cells, such as
the intrinsic telomerase activity (O’Hare et al. 2001). However, several secondary factors,
such as factors preventing proliferation or oxidative stress, can also affect the
immortalization results. Most immortalization methods used for hepatic cells have
involved the use of viral genes, most commonly the Simian virus 40 T antigen (SV40T) (Ali
& DeCaprio 2001). SV40T inactivates tumor suppressor genes (e.g. p53, pRb), but may also
induce telomerase activity in the infected cells. Viral oncogenes appear to disrupt many
cellular pathways and evoke undesirable changes, such as loss of differentiated properties
(Yeager & Reddel 1999). Most of the SV40T-immortalized adult hepatocyte lines express
several CYP enzymes (e.g. 1A2, 2C9 and 3A4) both at the mRNA and enzyme activity levels
(Pfeifer 1993, Akiyama et al. 2004, Mills et al. 2004, Ripp et al. 2006, Hariparsad et al. 2008).
The Fa2N-4 line, grown on collagen in a proprietary medium, has been used for the
assessment of CYP induction (Ripp et al. 2006). Cells immortalized by the overexpression of
telomerase (TERT), such as TTNT-1, have been shown to maintain a stable genotype and
retain critical phenotypic markers (Hahn & Meyerson 2001, Wege et al. 2003). hTERT
transfection has also been  used in the differentiation of mesenchymal stem cells into
hepatocyte-like cells (Liang et al. 2012).
Reversible or conditional immortalization can be achieved by the Cre-loxP system or
temperature sensitive SV40T (SVtsA58), which can be inactivated by increasing the
temperature (Cascio 2001, Daniele et al. 2002, Kobayashi et al. 2003). The immortalizing
gene is introduced into the cell in a vector between two loxP sites. After expanding the
immortalized  cells  in  culture,  the  reversion  can  be  achieved  by  transduction  of  Cre
recombinase and thus, removal of the inserted gene. The main drawback of these strategies
is the possible residual activity of the immortalising agent even after reversion (Hoekstra &
Chamuleau 2002). A reversibly immortalized adult hepatocyte line, NKNT-3, is
morphologically similar to hepatocytes and is functional in vitro, but the expression levels
or activities for CYP enzymes are somewhat limited (Kobayashi et al. 2000, Hoekstra et al.
2006). In addition, the cell line has been shown to be heterogenous and genetically unstable.
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The immortalization of primary cells was thought to be one way to provide functional and
differentiated cells in large quantities in order to compensate for the lack of homogenous
populations of hepatocytes. However, they do not function as normal cells due to the
mutations and karyotypic changes caused by the immortalization process and they have an
increased sensitivity towards neoplastic transformation (Drubin & Clawson 2004). Similarly
to tumour-derived cells, the expression of CAR and several hepatic uptake transporters are
also significantly lower than in HPHs (Hariparsad et al. 2008).
Stem cell -derived cell lines. In order to be defined as a stem cell, a cell must possess two
properties: 1) The ability to divide continuously, while maintaining the undifferentiated
state (self-renewal) and 2) The capacity to differentiate into specialized cell types
(Weissman et al. 2001). In adult tissues, somatic stem cells participate in the renewal or
regeneration of damaged tissues and are usually multipotent (Alison & Islam 2009).
Embryonic stem cells (ESCs) are pluripotent cells found in the inner cell mass of the
blastocyst (Hadjantonakis & Papaioannou 2001). Induced pluripotent stem (iPS) cells can be
artificially  derived from adult  somatic  cells  by inducing expression of  stem-cell  expressed
transcription factors (e.g. Oct4, Sox2, Klf4 and c-Myc) and have quite similar properties as
ESCs (Takahashi et al. 2007).
The differentiation of cell types during embryogenesis is mainly based on the presence of
critical growth factors, which induce cell type -specific expression of genes. In vivo, this
process consists of fine-tuned signalling, which is difficult to imitate in in vitro culture
conditions. The described phases of hepatic differentiation vary between groups and the
effects of individual factors have not been systematically studied. The first step is the
differentiation of the endoderm from the epiblast, a process regulated by TGF -related
Nodal and Wnt-signaling -proteins (D'amour et al. 2005). The differentiation of
hepatoblasts from the endoderm requires the presence of proteins from the fibroblast
growth factor (FGF) and bone morphogenetic protein (BMP) families (Lemaigre 2009).
Further differentiation also involves the hepatocyte growth factors (HGF), epidermal
growth factor  (EGF)  and oncostatin  M (OSM).  Transcription factors,  such as  Oct4,  Nanog,
FoxA2, Sox17, HNF and c/EBP, are expressed in the different phases of the differentiation
process and can be monitored during the in vitro differentiation (Keller 2005, Lemaigre
2009, Takayama 2012). Normally, an adult hepatocyte should not express alpha-fetoprotein
(AFP) and the expression of CYP3A7 should decrease while the expression of CYP3A4
increases (Daly 2006, Meier et al. 2006). The in vitro differentiation approaches used with
human  ESCs  often  rely  on  providing  the  established  growth  factors  with  minor
adjustments, such as the replacement of Nodal proteins with Activin A. The differentiation
into endoderm prior to growth factor addition significantly enhances the differentiation
into hepatocyte-like cells (Hay et al. 2008). In addition to growth factors, the differentiation
protocols sometimes involve the use of other cell types or matrices (Basma et al. 2009, Pei et
al. 2009). Hepatocyte differentiation continues during embryonic development and birth;
thus a short in vitro differentiation protocol may be impossible to develop (Lemaigre 2009).
Adult stem cells with stem-cell like properties have also been used to create hepatocyte-like
cells.  The  liver  contains  cells  which,  unlike  primary  hepatocytes,  can  be  cultured  and
possess some differentiation capacity but their exact function is unknown (Herrera et al.
2006, Alison 2009, Fonsato et al. 2010). When these cells are grown with HGF and FGF, they
start to differentiate into hepatocyte-like cells but this process requires the use of a special
bioreactor. Mesenchymal stem cells of bone marrow or adipose tissues and blood
monocytes have been coaxed by the above-mentioned growth factors to differentiate into
hepatocyte-like cells (e.g. Ruhnke et al. 2005, Sato et al. 2005, Ong et al. 2006, Zheng et al.
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2008, Saulnier et al. 2009, Snykers et al. 2011). The iPS cells have also been used to generate
hepatocyte-like cells using similar protocols as with the ESCs (Si-Tayeb et al. 2010, Sullivan
et al. 2010). The presence of iPS cells has also enabled the generation of hepatocyte-like cells
with  different  genotypes,  which  could  be  used  to  study  the  interindividual  differences  in
drug metabolism (Sullivan et al. 2010).
Adult cells do not suffer from similar ethical problems as ESCs and would be more readily
available. If successfully differentiated, these cells could provide a good source for in vitro
DM testing (Pouton & Haynes 2005). The cells could also be used in bioartificial liver
devices and for hepatocyte transplantation to treat metabolic liver diseases (Nussler et al.
2006). One problem is that the cells may later transdifferentiate into possibly cancerous cells
in the body. Some of the differentiated hepatocyte-like cells and their properties are
presented in Table 5. Often, the cells have not been adequately characterized especially for
their DM properties and their suitability for DM studies is difficult to assess.
2.3.4.3 Modifications on hepatic cell lines
A differentiated cell in any tissue has a limited ability to proliferate. Conversely, an increase
in the proliferation rate effectively means a decrease in differentiation. All cell types also
adapt to the in vitro environment through physiological or morphological changes. The
common cell culture plate and growth media can keep the cells alive but may not maintain
their in vivo differentiated properties. Thus, different modifications have been applied to
increase the expression and functionality of DMEs in both HPHs and continuous cell lines.
The most direct way to increase protein expression is to transfect the desired gene into a
cell line. For example, the HepG2 cell line has been transfected with various CYP cDNAs,
which are expressed for long periods of time (Yoshitomi et al. 2001, Tolosa et al. 2011).
However, since in vivo, multiple enzymes are responsible for the metabolism of xenobiotics,
a cell line overexpressing a single CYP gene can only be used to study the metabolism of a
compound by that particular enzyme. Controlled expression of transfected genes can be
achieved in several ways, e.g. by a doxycycline-inducible gene regulation or by adenoviral
vectors (Goldring et al. 2006, Aoyama et al. 2009). The controlled expression of CYPs could
allow tuning of the protein levels to resemble those observed in vivo. In addition, the lack of
transcription factors could be one reason for the low CYP expression in hepatoma cell lines
(Aninat et al. 2006, Ding et al. 2006, Hariparsad et al. 2008, Pelkonen et al. 2008). A stable
transfection of CAR and PXR into the small intestine model Caco-2 has increased the
expression of several CYP mRNAs (Korjamo et al. 2005 and 2006) and, the transfection of
C/EPB into HepG2 has also increased the expression of CYP2 family members but the
CYP3A4 expression requires cotransfection of HNF3. Similarly, the expression and
activity levels of CYP2B6 approach those of HPHs after transfection of C/EPB, HNF4 and
CAR to HepG2 (Jover et al. 1998, Rodríguez-Antona 2003, Benet et al. 2010). Due to the
complexity of the regulation of xenobiotic metabolism, especially the number of factors
involved, the restoration of a hepatocyte-like phenotype in hepatoma cells by gene transfers
may be impossible.
Multiple chemicals or media formulations increase the expression or activity of CYP
enzymes and other factors in HPHs and hepatoma cell lines (Table 6.). This indicates that
these agents are able to enhance the maintenance of hepatic functions or to promote the re-
differentiation in the cells. It should be kept in mind that some of the compounds may also
act as xenosensor ligands (e.g. retinoic acid and CAR) and thus, the increased expression of
CYPs would be due to induction and not differentiation (Chen et al. 2010b). The medium
formulation is especially crucial for HPHs if they are to maintain their specific functions.
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Table 6. Examples of modifications on hepatoma and HPH cultures.
Modification Hepatoma cell lines Primary hepatocytes References
Chemicals
Insulin
DEXa
DMSO
TSAa
Vitamin E
Modest (2-3-fold)
increase in hepatic
marker and albumin
expression.
Increases CYP3A4
expression together with
rifampicin (HepG2).
Increase in NR and CYP
expression and CYP
activity. Decreased
induction by classical
inducers (HepaRG).
Increase in the
expression of hepatic
transcription factors
(HepG2). Changes in
morphology and growth.
2-fold increase in CYP3A
activity
Enhances cell response to
growth factors in vivo. CYP2E1
activity increased / CYP3A
activity decreased in vitro
(rat).
Stabilization of morphology
and function (long-term
cultures). < 2-fold increase in
CYP mRNA expression and
activity (2B and 3A).
Max. 3-fold increase in the
CYP1, CYP2 and CYP3A mRNA
expression.
Promotes functional and
morphological differentiation
and prevents apoptosis.
Positively affects the CYP-
mediated biotransformation
(rat).
3-15 -fold increase in CYP3A
and CYP2 mRNA expression.
Kang-Park et al. 1995
Woodcroft & Novak 1997,
1999
Luo et al. 2002
Faucette et al. 2004
Maruyama et al. 2007
Nishimura et al. 2003
Aninat et al. 2006
Yamashita et al. 2003
Henkens et al. 2007
Landes et al. 2003 Brigelius-
Flohe 2005
Culture
conditions
Confluency
Co-culture
Matrigel
Increased CYP activity,
albumin and
transcription factor
expression and
hepatocyte-like
morphology (BC2,
Huh7).b
Increase in CYP
expression (HepG2 +
bovine endothelial cells).
No effect (HepG2).
Increased CYP1A1/2
activity (C3A).
90% confluence recommended
to avoid detaching. Cell-cell
contacts are important for
maintaining differentiated
properties.
Longer functional lifespan
(fibroblasts/biliary epithelial
cells, rat)
Improves morphology,
increase in expression of genes
involved in drug metabolism
and decrease in the expression
of some proteins, e.g.
cytokeratins.
Gómez-Lechon et al. 2001
Hamilton et al. 2001a
Sivertsson et al. 2010
Hamilton et al. 2001a,b
Ohno et al. 2008
Page et al. 2007
Sung et al. 2009
a DEX = dexamethasone, TSA=Trichostatin A (antifungal antibiotic and mammalian HDAC
inhibitor) b Polygonal shape and two nuclei
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The use of serum is not recommended due to the changes in hepatic morphology, such as
the inhibition of bile canaliculi formation (Runge et al. 2000, Tuschl et al. 2009).
The different matrix components of the epithelial cells of bile ducts and blood vessels form
the extracellular matrix (ECM) scaffolds to which hepatocytes attach in vivo. They provide
mechanical  integrity  and  act  as  dynamic  modulators  of  various  cellular  processes.  This
essential environment has been simulated by different culture matrices, e.g. the ECM
isolated from liver tissue or co-culture of epithelial or mesenchymal cells (Castell & Gómez-
Lechón 2009). In comparison to conventional monolayer culturs on collagen I, often used to
culture  HPHs,  a  sandwich  culture  can  enhance  the  expression  of  many  liver  specific
proteins, such as albumin, and to maintain these specialized functions for a longer period of
time (LeCluyse 2001, LeCluyse et al. 2005, Meng 2010). The sandwich culture provides a
more liver-like morphology with functional bile canaliculi and correct localization of efflux
transporters and thus, allows studies on hepatic metabolism, transport-mediated uptake
and biliary excretion of substrates for example to determine mechanisms of hepatotoxicity
(Sahi 2006, Ogimura et al. 2011, Schaefer et al. 2012).
Different  matrices  have also  been used for  hepatoma cell  lines.  HepG2 and C3A cell  lines
form  cell  clusters  on  3D  polystyrene  matrices  or  natural  hydrogels,  such  as  Matrigel  and
alginate, which can promote differentiation as shown by the increase of albumin or CYP
expression (Elkayam et al. 2006, Bokhari et al. 2007). When culturing continuous cell lines,
the cells are normally split either before or at confluency (Gómez-Lechón et al. 2001), which
prevents any long-lasting contacts with neighbouring cells. For example, the BC2, Huh7
and HepaRG cell lines require a period of confluency for differentiation (Table 4., Gómez-
Lechón et al. 2001, Aninat et al. 2006). In contrast, growing HepG2 cells in confluent
cultures does not seem to alter CYP expression (Ohno et al. 2008).
2.3.5 Liver slices and perfused liver
Precision-cut liver slices are physiologically relevant models for the metabolism of
xenobiotics, mainly because they retain an intact cellular tissue architecture, a wide range
of inducible Phase I and II enzymes and cofactors as well as transport proteins (Ekins et al.
2000, Edwards et al. 2003, Jia & Liu 2007, Olinga et al. 2008). Due to the poor circulation,
poor permeability or slow transport through the cell layers, the metabolism is generally
slower  in  liver  slices  than in  HPHs.  Thus,  the  thickness  of  the  slice  is  crucial  both for  the
cellular and architectural integrity and for adequate diffusion. A perfused liver would be
the best model of the in vivo situation, but so far, human livers have not been used and
experiments on animal livers have been performed only a very small scale (Brandon et al.
2003). The main problems associated with both models are their suitability only for short-
term studies, poor reproducibility of the experiments and species specific differences when
using animal-derived tissues (Brandon et al. 2003). Both methods are also labour-intensive
and require special instrumentation. Even though the xenosensor pathways and thus, the
induction of DMEs and DTs, are functional, these methods have been used almost
exclusively in metabolism and toxicity studies (Vermeir et al. 2005, Olinga et al. 2008,
Elferink et al. 2011).
2.3.6 In vivo models
In vivo models, i.e. laboratory animals and human clinical trials, incorporate the parallel
dynamic ADME processes missing from static in vitro assays. Although some induction
studies of CYP3A4 with known inducers have been conducted to compare the activity
between healthy volunteers and isolated HPHs, human clinical studies are mainly used in
the  late  development  phases  of  new  drug  molecules  (e.g. McCune et al. 2000). The use of
41
animal models is associated with the problem that the data cannot be extrapolated to
humans due to species differences in the isoforms, catalytic activities and expression levels
of CYPs (Martignoni et al. 2006, Pelkonen et al. 2008, Puccinelli et al. 2011). As discussed
earlier, also xenosensors display similar variation.
The mouse has a shorter lifespan, faster breeding, larger litter sizes and lower maintenance
costs compared to other rodents or larger animal models and is thus the most widely used
animal model (Cheung & Gonzalez 2008). In attempts to overcome the problems arising
from species differences, various knock-out (loss of function), transgenic (gain of function)
and humanized mouse models  have been developed for  the  xenosensors  and many CYPs
(Lin 2008). Both PXR and CAR null mice have a normal phenotype, are viable and fertile,
but the induction of Cyp3a11 and Cyp2b10, respectively, is lost. These animals do not
metabolize endo- or exogenous toxicants effectively and are thus prone to serious liver
damage (Staudinger et al. 2001, Zhang et al. 2002). The CAR null mouse has been important
in  the  discovery  of  the  role  of  CAR  in  bilirubin  and  bile  acid  metabolism  (Huang  et  al.
2003). The AhR knockout mice exhibit decreased liver size, decreased expression of
CYP1A2 as well as resistance to TCDD-elicited CYP1A1 induction (Gonzalez & Fernandez-
Salguero 1998, Mimura & Fujii-Kuriyama 2003). Most of the CYP null mice have a normal
phenotype and the loss of enzymes in general does not result in any significant changes in
development or cause any abnormal physiology (Gonzalez 2003).
A transgenic or humanized mouse can be generated by various techniques (Cheung &
Gonzalez 2008). Since most transcription factors are conserved in mammals, it is assumed
that the replacement of the mouse TF by the human counterpart will maintain regulation of
the target gene in the transgenic animal. The simplest approach is to introduce a human
xenosensor- or CYP-coding cDNA, under a tissue-specific promoter controlling the
expression of the gene, or a whole human gene, containing all of the regulatory elements,
into  an  animal  by  pronuclei  injection  or  by  using  genomic  clones,  respectively.  Since  the
resulting  animals  still  harbour  the  corresponding  murine  genes,  they  may  exhibit
overlapping functions and this may interfere with the expression or function of the human
transgene. Thus, a better approach is to introduce the human transgene into a knockout
animal  either  by  direct  incorporation  (knock-in)  of  the  human  gene  (cDNA)  to  the  site  of
the endogenous mouse gene or by breeding the hNR transgene into the mNR knockout
background. The xenosensor or CYP-humanized mice could be used to predict potential
toxicological and metabolic problems and to overcome the species differences in the in vivo
drug metabolism studies.
Different transgenic PXR mice have been created by fusing the hPXR cDNA to albumin or
fatty acid binding protein (FABP)-promoters with or without the (constitutively active)
VP16 coactivator  and breeding the transgene onto the murine Pxr-null background (Xie et
al. 2000, Zhou et al. 2006). In these mice, the endogenous Cyp3a11 gene  is  induced  by
known  human  PXR  inducers,  such  as  rifampicin,  but  only  minimally  by  the  mouse  PXR
ligand PCN. Similarly, CAR-humanized mice have been produced with the albumin
promoter-driven hCAR cDNA (Zhang et al. 2002). The AhR-humanized mouse, resistant to
target gene induction by TCDD, has been generated by knocking in the human AhR cDNA
into  the  mouse  AhR  gene  promoter  (Moriguchi  et  al.  2003).  Various  transgenic  CYP  mice
(e.g. CYP1A1/2, 2A6, 2C18/19, and 3A4), which exhibit metabolic activity similar to humans
in vivo,  have been generated (Gonzalez & Yu 2006, Cheung & Gonzalez 2008, Uno et al.
2009, Hasegawa et al. 2012). These models have been used to study the differences in CYP-
mediated metabolism between the two species, to determine the mechanisms of regulation
of the human gene and to search for potential endogenous substrates for the enzymes.
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Another approach is to transplant human hepatocytes into an immunodeficient mouse and
thus, to generate humanized livers (“chimeric mouse”, Tateno et al. 2004). CYP enzymes as
well as PXR and CAR have been shown to be expressed at near normal (human) levels in
these mice and the inducibility of at least CYP1A2 and CYP3A4 was shown to be similar to
hepatocytes (Emoto et al. 2008, Katoh et al. 2008). Further, double humanized mice (e.g.
PXR/CYP3A4) could provide even better models for biotransformation studies or drug
development (Felmlee et al. 2008, Cheng et al. 2011).
2.3.7 Summary
Obtaining valid information on the different factors involved in drug metabolism is critical
for  drug  discovery  and  development,  but  also  for  the  understanding  of  the  molecular
mechanisms behind the function of the xenosensors and CYP enzymes. For drug
development, the main aim is to increase safety and efficacy of new drugs as well as to
lower the costs of the drug development process. As described in the previous sections,
multiple in vitro and in vivo methods, involving numerous different technologies and
instrumentation, exist with which to study xenosensor and CYP function and xenobiotic
metabolism. Each of these systems has unique properties and all of them can provide some
useful information. But how should one choose the most appropriate method for the
phenomenon under study?
In most cases, the different in vitro or in silico methods can serve as an initial screen to rule
out metabolic pathways or to predict xenosensor activation or CYP induction. They can
also produce results which can be further used to plan or interpret toxicological and clinical
studies.  The  appropriate  design  of  an  experiment  as  well  as  proper  validation  and
understanding of the method, and the mechanisms by which all the biological components
function, is essential for the correct evaluation of the properties (e.g. induction potential) of
different compounds. In addition to the appropriate experimental conditions, the choice of
positive and negative controls, incubation times/endpoints as well as relevant
concentrations of both study compounds and controls are critical for making effective and
correct interpretations or conducting in vivo extrapolations of the obtained data.
In essence, all of the assays described in the previous sections have their own advantages
but also certain disadvantages or limitations (Table 7.) and thus at the moment, the use of
several  different  methods  (in  sequence)  to  study  the  different  aspects  of  xenobiotic
metabolism produces the best results (Gómez-Lechón et al. 2007, Pelkonen et al. 2008). As
described previously, the models are also constantly being developed to be better suited for
studies in drug discovery and development.
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3 Aims of the study
The main aim of this study was to develop different cell-based models and to complement
them with other in vitro and in silico methods for studies on human xenosensors.
The specific aims were as follows:
1. To compare the impact of different natural and chimeric transcription factors on
CYP expression in hepatoma cells and to develop novel genetically modified
hepatoma cell lines expressing chimeric hCAR and hPXR receptors.
2. To develop optimized and validated screening assays for human xenosensor
activation.
3. To  find  novel  selective  agonists  and  inverse  agonists  for  human  CAR  by  using
virtual screening techniques and different in vitro assays.
4. To use these methods to study the essential ligand characteristics to achieve specific
activation of hCAR and the induction of CYP enzymes.
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4 Materials and methods
4.1 CHEMICALS
The commercial chemicals were of at least analytical grade and their suppliers, as well as
dilution media, have been specified in the original publications (I-IV). Chemicals identified
by  virtual  screening  were  ordered  from  Tripos  Inc.  (St.Louis,  MO,  USA)  (I, III)  or  from
Maybridge  (Trevillet,  UK)  (IV). S07662, flexible diaryl (FL) compounds, TPP and TMPP
were synthesized and purified as described in the original publication IV, Pulkkinen et al.
2008 and Honkakoski et al. 2004, respectively. Meclizine was a kind gift from Drs.
Hongbing Wang (University of Maryland, MD) and Tatsuya Sueyoshi (NIEHS, NC).
4.2 PLASMIDS
The constructs were created by standard DNA cloning protocols (Sambrook and Russell
2001) and verified by dideoxy sequencing. The plasmids were amplified in DH5 and XL10
strains of E. coli and purified with Qiagen columns (Hilden, Germany).
NR expression vectors. The CMX-GAL4-LBD constructs of hCAR (residues 108-348) and
hPXR (107-434) have been described in Mäkinen et al. 2002 and the mutated hCAR LBD
constructs in Jyrkkärinne et al. 2005 (I, III, IV). The full-length, wild-type hCAR (residues
1-348) and hPXR (residues 1-434) expression vectors have been described in Mäkinen et al.
2002 and Korjamo et al. 2005. For chimeric constructs (Figure 8.),  the full  length NRs were
fused either N- or C-terminally with the fragment containing the nuclear localization signal
and the activation domain (AD) of the human NF subunit (residues 284-551; designated
as "p65"), as described in detail in the original publication II.
Reporter plasmids. The hPBREM-tk-luciferase, mutated hPBREM-tk-luciferase, hCYP2B6-
luciferase and (ER6)3-tk-luciferase have been previously described in Sueyoshi et al. 1999,
Honkakoski et al. 1998 and Mäkinen et al. 2002. CYP3A4-XREM-luciferase (Goodwin et al.,
1999) was donated by Dr. Chris Liddle (University of Sydney, Westmead, Australia),
GAL4-responsive UAS4-tk-luciferase by Prof. R.M. Evans (Salk Institute, La Jolla, CA) and
the CYP1A1 promoter-driven luciferase by Dr. Stephan Safe (Texas A&M Health Science
Center, TX).
Constructs for the mammalian 2-hybrid assay (I, III and IV). The NR interaction domains
of co-repressor NCoR (residues 1972-2290) and co-activator SRC1 (residues 547-789) were
cloned in-frame downstream of the GAL4-DNA-binding domains between the EcoRI and
BamHI sites of the pM vector (Matchmaker kit, BD Clontech) and the NdeI and BamHI sites
of the CMX-GAL4-vector, respectively. The human CAR LBD (residues 108–348) was fused
with the VP16 transactivation domain present in the pVP16 plasmid. The luciferase
reporter pG5-luc was purchased from Promega (Madison, WI, USA).
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Figure 8. Schematic presentation of the chimeric NR constructs and their function. A) All
constructs contain amino acids 284-551 of p65 activation domain. CMV prom = cytomegalovirus
early promoter,  TA2/TA1 = transactivation domain 1 and 2,  NLS = nuclear localization signal,
SV40 Late poly(A) = simian virus 40 polyadenylation signal. B) The chimeric receptors with the
added activation domain (AD) exhibit higher trans-activation potential compared to the wild
type receptor without ligand.
4.3 CELL CULTURE
The  continuous  cell  lines  were  maintained  as  described  in  the  original  publications  and
passages between 3 and 30 were used in the experiments (I-IV). The human hepatoma cell
line C3A (ATCC CRL-10741) was used in most of the assays. Different cell lines (ARPE-19,
HEK293, HepG2, C3A) were tested in pilot studies for their NR responses, ease of culturing
and transfection efficiency.  The C3A cells  are  easily  transfected,  easy to  culture  and show
clear  and  reproducible  responses  in  NR  reporter  assays,  perhaps  reflecting  a  suitable
cofactor environment for NR function. They also express the AhR endogenously. In study
III,  the  more  commonly  used  HepG2  hepatoma  cell  line  was  used  to  compare  the
expression of the selected genes in these two related cell lines.
Human primary hepatocytes from donors with no known exposure to CYP inducers, were
obtained  from  BD  Gentest/BD  Discovery  Labware  (Woburn,  MA)  (I) or Biopredic
International (III, IV).  Upon  receipt,  the  medium  provided  by  the  supplier  was  replaced
and the cells were allowed to stabilize for 24-48 hours (Abadie-Viollon et al. 2010) before
chemical exposures, according to the supplier’s instructions. The cells were exposed to
DMSO or H2O (0.1%, v/v), selected test chemicals and reference compounds for 24 hours for
mRNA studies and for 48-72 hours for CYP induction studies.
Modified C3A cell lines expressing chimeric hPXR and hCAR were generated from wild-
type C3A cells by transfections of expression vectors for chimeric NR cDNAs described in
Section 4.2 and selected with G418 (Honkakoski et al. 2001). Proliferating G418-resistant
colonies were selected first based on hPXR/hCAR- responsive reporter gene activity and
subsequently with quantitative RT-PCR for CYP mRNAs (II).
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4.4 REPORTER GENE ASSAYS
The principles of the methods are described in Section 2.3.3 as  well  as  in  the  original
publications (I-IV). For the xenosensor activity assays and cofactor binding assays (hCAR,
M2H) (I, III, IV), C3A cells were seeded on 48-well plates and transfected with the calcium
phosphate method (Chen & Okayama 1987) and constructs described in the original
publications. The assays were optimized and validated by using control chemicals chosen
based on initial screening and NIH guidelines (modified for 48-well plates) as well as the
assay performance measures recommended in Iversen et al. 2006. The empty CMX-GAL4-
vector was used as a negative control for M1H assays and the SRC1 assay and the empty
pM vector for the NCoR assay. For the reporter assays with full length and chimeric hCAR
and hPXR constructs, HEK293 and C3A cells were seeded onto 48-well plates and
transfected with selected reporter genes with natural or mutated NR binding sites and NR
constructs (II). The empty pCI/neo vector was used as a negative control.
Stably transfected colonies (II)  were  expanded and tested for  the  chimeric  NR expression
and functionality by a transient transfection assay. Replicate cell aliquots were seeded on
48-well plates and transfected either with the NR-responsive luciferase reporter or the non-
responsive control. Positive and negative controls were prepared by co-transfection of
reporters and the appropriate chimeric construct or the empty pCI/neo vector, respectively.
Colonies yielding responses higher than the transient negative controls underwent further
testing.
After transfection, the medium was replaced with fresh medium including either a vehicle
control (DMSO or H2O, 0.1% v/v), reference compounds or test chemicals as described in
the original publications and incubated for 24 hours. After chemical treatment, the cells
were lysed and stored at -80ºC at least overnight to completely lyse the cell membranes and
to maintain the functionality of the enzymes. Luciferase and -galactosidase activities were
measured from the cell lysate (Honkakoski et al. 2001) using the Victor multiplate reader
(PerkinElmer, Turku, Finland) and the luciferase activity was normalized to the control -
galactosidase activity of each respective sample.
4.5 YEAST 2-HYBRID ASSAY
The yeast 2-hybrid assay is essentially based on the same principle as its mammalian
counterpart described in Section 2.3.3. However, the NR and coregulator constructs differ
in that the NR LBD is fused with the yeast GAL4 DBD and the coregulator with the GAL4-
AD. The NR/DBD construct binds to the yeast genomic LacZ gene and the coregulator/AD
construct binds the activated NR, thus enabling the expression of the -galactosidase gene.
The pGBKT7 and pGADT7 plasmids (Matchmaker GAL4 Two-Hybrid System 3, Clontech,
CA) encoding the human CAR LBD and the human NCoR interaction domain have been
described (Jyrkkärinne et al. 2005) Yeast colonies expressing both CAR LBD and the
interacting partner (NCoR) were grown, treated with DMSO vehicle (0.1 % v/v) or selected
test chemicals and assayed for -galactosidase activity, cell density and turbidity as
described in Mäkinen et al. 2002. The -galactosidase activities were normalized to cell
density.
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4.6 GENE EXPRESSION STUDIES
Effects  of  unmodified  and  chimeric  NRs  and  NR  ligands  on  CYP  expression  in   wild
type C3A cells (II). In order to determine the effects of NR agonists and/or transiently
transfected  natural  and  chimeric  NRs  on  CYP  expression  (II),  wild  type  C3A  and  HepG2
cells were seeded onto 6-well plates one day before transfection (C3A) or three (C3A) and
five (HepG2) days before exposing to NR agonists. C3A cells were transfected with
chimeric and natural NR expression vectors by polyethyleneimine (PEI) 25 or calcium
phosphate precipitation as described in the original publication. Standard growth medium
in the absence or presence of NR agonists was added to selected wells and the cells were
incubated for 48 h before measurement of CYP mRNAs. The empty vector (pCI/neo) was
used as a negative control.
Effects of FoxA2 and HNF4 on CYP expression in wild type C3A cells (unpublished).
Wild type C3A cells were grown and transfected with human HNF4 or FoxA2 expression
vectors (SD123863 and SC327867, Origene, MD) by calcium phosphate precipitation as
described above. After 24 hours, the medium was replaced with standard growth medium.
The mRNA expression of CYP2B6 and CYP3A4 was measured after 48 hours and 7 days of
culture and the expression levels were compared to non-transfected cells.
Nucleic acid isolation. Total RNA from 6-well plates was isolated with TRI Reagent
(Sigma) and any contaminating DNA was removed using the DNase Free kit (Ambion,
Austin, TX). The RNA was quantified with RiboGreen dye (Molecular Probes, Netherlands)
and 2 μg of RNA was reverse transcribed to cDNA with M-MuLV reverse transcriptase
(Fermentas, Hanover, MD) using random priming. The RNA from smaller culture plates
was isolated and reverse transcribed using the TaqMan Gene Expression Cells to Ct kit
(Ambion, Austin, TX) according to the manufacturer's instructions. The genomic DNA was
isolated from selected cell lines (II) with standard proteinase K treatment, phenol-
chloroform extraction and ethanol precipitation and treated with RNase to remove any
residual RNA contamination.
Quantitative RT-PCR. All studies were done using TaqMan chemistry, which uses a
fluorogenic  probe  for  the  detection  of  a  specific  product  as  it  accumulates  during  PCR
cycles, and an ABI Prism 7500 instrument (Applied Biosystems, UK). Forty ng of the cDNA
obtained from 6-well plates or samples with an unknown cDNA amount obtained with the
TaqMan Gene Expression Cells to Ct kit were used in the PCR reaction. The fluorescence
data were processed in the QGene program (Müller et al. 2002) and the results were
calculated according to comparative Ct-method assuming equal amplification efficiencies
of 2.  The measured CYP levels were normalized either to total RNA or to selected control
gene expression (Bustin 2000 and 2002). The primers and probes and the liver sample used
as a positive control (II) are presented in the original publications (I-IV). For copy number
determination, primer/probe sets for hPXR and hCAR were used for detection of the
integrated chimeric NR cDNAs. The used probes are able to span an exon/exon junction
and can detect the transgenic cDNA with no intronic sequences but cannot detect genomic
CAR or PXR gene sequences. Dilutions of corresponding chimeric NR plasmids were used
as standards.
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4.7 METABOLIC EXPERIMENTS
Fluorometric assays (II, III, unpublished). The  metabolic  activity  of  CYP3A4  (II,
unpublished results) was measured with a fluorometric assay from a lysate obtained from
wild type and modified C3A cells, with or without chemical treatment, grown on 6-well
plates. The lysate was incubated in buffer containing the substrate (BFC) with or without
the CYP3A4 specific inhibitor, ketoconazole. BFC is dealkylated into fluorescent HFC by
CYP3A4, CYP1A2 and to a lesser extent by CYP2B6 (Donato et al. 2004). Ketoconazole, at
the chosen concentration (5 μM), is sufficient to inhibit all CYP3A4 activity (Turpeinen et al.
2005), thus making it possible to differentiate the BFC metabolism catalyzed by CYP3A4
from other CYP enzymes. Microsomes obtained from the human liver sample HL24 were
used as a positive control. The CYP3A4 and CYP2B6 inhibition potential of selected
chemicals (III) was studied with cDNA expressed recombinant enzymes (BD Gentest,
Franklin Lakes, NJ) in 96-wells as described by Salminen et al. 2011. The incubation
mixtures, containing the recombinant CYP enzymes, probe substrates (BFC for 3A4 and
EFC for 2B6) and test chemicals, have been described in detail in the original publication.
The reference inhibitors were ketoconazole for CYP3A4 and ticlopidine for CYP2B6. All
dilutions of substrates and test chemicals were prepared so that the final concentration of
the solvent (ACN or DMSO) did not exceed 0.1% v/v. The plates were pre-incubated in
+37ºC for 10 min and the NADPH-regenerating system was added to start the reaction. The
plates were then incubated in 37ºC for 6 hours (activity, II) or 20 min (inhibition, III).  A
standard curve (0–1000 nM) was constructed from HFC. The fluorescence was measured at
405/535 nm with VICTOR2 multiplate reader.
LC-MS/MS (III). The compounds in the sample are first separated by liquid
chromatography (LC) and then introduced into the mass spectrometer (MS), which
measures the mass-to-charge ratio of charged particles (Korfmacher 2005). Hepatocytes on
48-well plates were treated as described in Section 4.3. Salicylamide was used to saturate
the conjugation enzymes and the samples were incubated with CYP specific substrates
(testosterone for CYP3A4 and buproprion for CYP2B6). The samples were then analyzed
for the amounts of CYP isoform specific metabolites as described by Tolonen et al. 2007.
4.8 RECOMBINANT HUMAN CAR-LBD PROTEIN PRODUCTION AND
LIMITED PROTEASE DIGESTION ASSAY (III, IV)
The limited protease digestion (LPD) assay is based on the principle that a conformational
change  of  the  LBD  may  limit  access  to  a  cutting  site  for  a  protease  and  thus,  create  a
protease-resistant receptor fragment. These assays have been used to analyze NR ligand
binding, ligand-induced conformational changes to the LBD and to characterize the
functional conformations of the receptors (Reichman et al. 1984, Benkoussa et al. 1997,
Nayeri & Carlberg 1997). The detailed protocols have been described in the original
publications (III, IV). Briefly, the N-terminal His6-hCAR-LBD (residues 103-348) fusion
protein  was  produced  in E. Coli BL21  (DE3)  cells  and  purified.  The  resulted  recombinant
His6-hCAR-LBD was preincubated with DMSO or selected hCAR ligands and digested
with subtilisin. The obtained proteolytic fragments were denatured and analyzed with
SDS-PAGE.
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4.9 MOLECULAR MODELING
Two-step virtual screening procedures, based on a pharmacophore searches and molecular
docking studies, were used to screen large databases for novel hCAR ligands. The
principles of the methods have been described in Section 2.3.1.
In study I, the Tripos LeadQuest database and in study IV, the Maybridge database, were
used as starting points for the pharmacophore searches. Selected ligands were docked into
hCAR LBD (Protein Data Bank (PDB), crystal structure 1XVP, chain D) using GOLD
docking suite (version 2.2, CCDC, Cambridge, UK) and the docking site was defined either
within a sphere around atom CD1 of Leu206 (I) or using the ligand molecule (CITCO)
extracted from the crystal structure (IV). Compounds to be tested in biological assays were
selected according to their GoldScore and visual inspection. Possibilities for interaction
between ligands and the LBP were predicted by molecular interactions fields calculations
(I). The detailed features of the pharmacophores as well as docking protocols have been
explained in the respective original publications.
Selected ligands (III, IV)  were  also  docked to  the  1XVP with a  new version of  the  GOLD
docking suite (4.0), which allowed selected amino acid side chains to move freely ("flexible
docking").  The  docking  site  was  defined  using  the  ligand  molecule  (CITCO)  and  the  side
chains of amino acids F161 and Y224 were allowed to move freely, based on the data
obtained from previous MD simulations (Windshügel et al. 2005 and 2007). The rescoring
of the docking poses was done by calculating the theoretical binding energies of ligands
and the contact preference maps of ambiguous docking poses were inspected visually. The
best pose for each ligand was selected based on both the binding energy and the adequacy
of  the  interaction  fields.  Shorter  (1.0  ns, III)  or  longer  (10  ns, IV)  MD  simulations  were
performed for the best poses obtained from flexible docking to study the structural
behaviour of selected ligand/LBP complexes. The trajectories were analyzed for root mean
square deviations (RMSD), atomic positional fluctuation (APF) and protein secondary
structures and visually examined. The volume of the LBP and ligands were calculated in
order to evaluate the possible differences in the filling degree of the pocket by different
ligands, which was thought to influence the activity of the receptor. The detailed methods
are presented in the respective original publications and in Jyrkkärinne et al. 2012.
4.10 STATISTICAL ANALYSIS
The results are presented as mean ± SEM of at least 3 replicates. Student's paired t-test with
Bonferroni or Šidák correction was used to assess the statistical significance of the results.
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5 Main results and discussion
5.1 STUDIES ON CYP EXPRESSION IN HEPATOMA CELLS
The applicability of human hepatoma cell lines for drug metabolism and toxicity studies
has been questioned due to the downregulation of CYP enzymes in cultured cells. The
suggested mechanisms behind this phenomenon and different approaches to increase the
CYP  expression  have  been  discussed  in Section 2.3.4.  Since  the  gene  expression  levels  in
hepatoma cell lines vary depending on the culture conditions, the basal mRNA levels of
selected CYPs, NRs and NR cofactors were determined in C3A and HepG2 cell lines in
comparison with a single human liver sample giving a rough estimate of the transcript
levels in vivo (II). In general, the two hepatoma cell lines showed a similar expression
profile and the expression levels of the genes were clearly lower ( 1%) than in the liver
sample as described previously (Rodriguez-Antona et al. 2002, Westerink & Schoonen
2007a,b). However, the transcript levels of NCoR, PGC1, PXR and HNF4 were higher than
in  the  liver  sample  in  both  cell  lines,  whereas  the  levels  of  CYPs,  CAR  and  other
coregulators were very low. The high expression of HNF4 has been previously described
for HepG2 whereas, in contrast to the present finding, the PGC1 has been claimed to be
underexpressed in these cells (Martínez-Jiménez et al. 2006). The largest differences
between the two cell lines were in the expression levels of CYP2B6, PXR, TIF2 and NCoR,
with higher expression levels (260-fold in the case of CYP2B6) in the C3A cell line. C3A was
chosen for further studies mainly due to the higher expression of CYP2B6, the ease of
culturing, better transfection efficiency and reproducibility (unpublished observations) as
compared to HepG2.
5.1.1 Transient transfections and NR activators (II, unpublished)
One possible reason for the downregulation of CYPs in hepatoma cells is the lack of the
different  TFs  which  control  their  expression.  Both  PXR  and  CAR  regulate  the  inducible
expression of many DME genes and the expression of these NRs in general correlates with
the expression of CYP mRNAs in liver samples (Pascussi et al. 2001, Chang et al. 2003,
Vyhlidal et al. 2006, Wortham et al. 2007). Different modifications related to these receptors,
such as treating the cells with their agonists or transfecting the cells with the receptor
expression vectors, have been applied to increase or enhance the expression and activity of
CYPs in hepatoma cells (Section 2.3.4.3). The usefulness of the former technique depends
on the endogenous expression of PXR and CAR, whereas the latter approach can
upregulate numerous CYP and DT mRNAs, albeit modestly (Korjamo et al. 2006). In this
work,  the  effects  of  human  PXR  and  CAR  activators  as  well  as  the  overexpression  of
different TFs to the CYP mRNA levels or reporter activities were studied (Table 8.).
NRs and NR agonists. As expected, based on the NR mRNA levels of unmodified C3A
cells, the cells displayed only a modest response to a PXR but not to a CAR activator, which
is consistent with the low expression of CAR in hepatoma cells (Zelko & Negishi 2000). The
overexpression of hPXR or hCAR increased the expression of CYP3A4 and CYP2B6
mRNAs  only  slightly  and  further  treatment  with  NR  agonists  could  only  increase  the
expression of CYP3A4. Even though PXR is expressed in the C3A cells at the mRNA level,
the protein might be non-functional due to the unfavourable expression levels of cofactors
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in these cells (low SRC1, high NCoR) or due to the expression of splice variants (Donato et
al. 2008, Lamba 2008, Zhang et al. 2008). Ligand-free PXR is also known to associate with
corepressors decreasing its activity (Johnson et al. 2006). However, due to the over 2-fold
increase in CYP3A4 expression by RIF, the wild type C3A contains at least a small amount
of functional PXR, as reported by others for HepG2 (Fery et al. 2010).
Chimeric NRs. The  modular  structure  of  NRs  generally  allows  the  modification  of  the
receptor by addition of other transcription factor domains to modulate their function
(Germain et al. 2006). Thus, a strong activation domain (AD) of the p65 subunit of the
nuclear factor B was fused to both hPXR and hCAR either at the N- or the C-terminus in
order to create receptors with constitutively enhanced activity. Similar approaches using
herpes simplex viral protein 16 (VP16-AD) have been used to generate exdysone-inducible
regulator and in mice, the NR-VP16 fusion proteins have been shown to increase the
expression of NR target genes (No et al. 1996, Rosenfeld et al. 2003, Saini et al. 2004). The
functionality of the constructs was tested with reporter assays: Whereas the wild type
receptors had a  modest (less than 5-fold) effect on the reporter gene expression even with
added agonists, the chimeric receptors displayed a strong constitutive activation of both
CYP3A4 (20- to 28-fold) and CYP2B6 (9- to 16-fold) promoter driven reporter constructs
(Table 8.). Furthermore, all chimeric constructs notably increased the CYP3A4 expression
(hCAR: 6- to 30-fold, hPXR: 8- to 10-fold) (Table 8.).
Interestingly, the hCAR constructs, especially the version with the C-terminal AD,
exhibited higher activation of CYP3A4/XREM- and ER6-reporters and higher upregulation
of  CYP3A4  mRNA  than  either  of  the  hPXR  constructs.  The  natural  CYP2B6  driven  and
heterologous hPBREM reporters exhibited highest activation by the hCAR with N-terminal
AD, while the hPXR mediated activation was modest or even decreased by over 50%
compared to empty vector. The hPXR construct with the N-terminal AD was slightly better
than  the  C-terminal  AD  in  most  assays.  These  differences  could  be  due  to  the  stronger
activation potential of the chimeric hCAR constructs as such, which is also seen in HEK293
cells,  or  the  impaired  function  of  hPXR  constructs  in  this  particular  cell  line,  since  in
HEK293 cells the differences in reporter activity between different constructs were not as
pronounced. In summary, the activation profile of the CYP3A4 reporters was in general
very similar to the expression profiles of CYP3A4 mRNA.
HNF4 and FoxA2 (HNF3) (unpublished). As explained in Section 2.2, HNF4 regulates
many hepatic genes involved in the differentiated function of hepatocytes and is
responsible for the basal expression of liver specific genes. The receptor also regulates the
hepatic expression of different CYPs and reduction of HNF4 protein significantly
decreases at least the 3A4 mRNA levels in HepG2 cells (Akiyama et al. 2004, Matsumura et
al. 2004). It is also required for the expression of PXR and thus, may also affect the CYP3A4
expression via this pathway (Li et al. 2000). The forkhead box transcription factor A2
(FoxA2,  previously  HNF3)  is  involved in  the  energy metabolism,  bile  duct  development
and bile acid homeostasis (Wolfrum et al. 2004, Li et al. 2009). It is also involved in the
endoderm differentiation via binding to the sequences required for hepatocyte-specific
expression of genes and activated during the differentiation of definitive endoderm
(Kaestner 2000). The deletion of FoxA2 in mice results in a significant decrease in the levels
of certain proteins, such as PXR and Cyp3a11 (Bochkis et al. 2008). In addition, a significant
correlation between FoxA2, PXR and CYP3A4 levels in human hepatic samples has been
shown (Lamba et al. 2010).
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Table 8. CYP2B6 and 3A4 reporter gene activity and mRNA expression in C3A cell lines
The results are expressed as fold-increase in activity or expression compared to untreated or
wild type C3A cells. N.D. = not done,  = 1-2.5 -fold,  = 2.5-5 -fold,  = 5-10 -fold,  =
over 10-fold,  = less than 1-fold, RGA=Reporter gene activity: CYP3A4.XREM.distal.luc/
(ER6)3.tk.luc for CYP3A4; hPBREM.tk.luc/ CYP2B6.luc for CYP2B6, CYP3A4.XREM.distal.luc for
stable transfectants, *unpublished results
A moderate increase of the expression of both CYP2B6 (2 to 3 -fold) and CYP3A4 (4 to 6-
fold)  was  observed  only  after  7  days  of  culture  (Table 8.) after transient transfection of
either  HNF4 or  FoxA2.  The  somewhat  delayed  effect  might  be  due  to  indirect  or
secondary (via other TFs) effects on CYP expression. Interestingly, even though the C3A
shows high levels of HNF4 (see above), transfection of the gene increased the CYP mRNA
expression, suggesting that the endogenously expressed HNF4 is not fully functional. In
particular, PGC1 is considered to be a key coactivator for sustaining the expression of
HNF4-dependent genes in hepatoma cells and thus, the lack of functionality has
previously been suggested to be due to the observed low levels of SRC1 and PGC1
(Martínez-Jiménez et al. 2006). As the present results revealed that the PGC1 was
expressed at higher levels than in the liver sample, the lack of (endogenous) HNF4
functionality  could  be  due  to  the  levels  of  other  cofactors  (such  as  the  high  levels  of
corepressor NCoR). However, these results show that the CYP mRNA levels can be
upregulated also by the overexpression of HNF4 and FoxA2.
5.1.2 Generation of stable cell lines expressing chimeric PXR and CAR (II)
Previously, the upregulation of CYP expression HepG2 and Caco-2 cells has been achieved
by stable transfections of TFs, such as c/EBP, HNF4, CAR and PXR (Jover et al. 1998,
Sueyoshi et al. 1999, Naiki et al. 2004, Korjamo et al. 2005, 2006, Trubetskoy et al. 2005). Due
to their promising transactivation properties, chimeric NRs were used to develop stable
C3A cell lines. The use of chimeric receptors to modulate CYP levels in hepatoma cells has
not been previously published. The majority of the obtained positive colonies (80%), chosen
based on reporter gene activities, were based on hCAR-chimeras, which also showed a
higher transactivation potential in transient transfections (Section 5.1.1). This could be due
CYP3A4 CYP2B6
RGA mRNA RGA mRNA
NR agonists
Transient transfections
- wild type NR
- p65-NR
- NR-p65
- HNF4*
- FoxA2*
N.D.
-


N.D.
N.D.
(CITCO)
 (RIF)
-

 - 
(48h)
 (7d)
 (48h)
 (7d)
N.D.
/
- / -
- / -
N.D.
N.D.
 (CITCO)
 (RIF)

N.D.
N.D.
 (48h)
 (7d)
 (48h)
 (7d)
Stable transfections
- p65-NR
- NR-p65
-

-
-
N.D.
N.D.
-
-
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to the lower expression of endogenous CAR in C3A cells or simply to a random integration
of the transgene. It was also recently shown that the PXR-mediated upregulation of the p38
MAPK signaling resulted in morphological changes and migration of HepG2, while cell
growth itself not affected (Kodama & Negishi 2011). No significant morphological changes
were  observed in  the  hPXR sublines  by microscopy but  no detailed studies  were  done on
the effects of the overexpression of the constitutively active receptor construct on cellular
functions. Furthermore, the CYP3A4 reporter activities used to select the colonies for
further testing did not correlate with the later measured CYP3A4 mRNA levels and thus,
the use of reporter based method is not necessarily the best choice for the selection of
positive colonies.
The mRNA levels of CYP2B6, 2C9 and 3A4 were increased somewhat differently in the
sublines. All hCAR sublines showed increased levels of all three CYPs, whereas the hPXR
sublines showed a decrease in CYP2B6 expression, compared to the unmodified cells. The
increase in expression was most impressive with CYP2C9 but nonetheless the expression
levels still remained below those of the liver sample. In contrast, CYP2B6 expression levels
were close to or exceeded the levels of the liver sample. The mRNA levels of at least
CYP2B6 and CYP3A4 have been shown to be stable throughout continuous passaging for
several months and between different stocks of individual sublines (unpublished
observation). Most of the modified cell lines also showed slightly elevated CYP3A4
function compared to the wild type C3A cells. The subline hCAR28 was considered to be
the most promising cell line due to the overall enhancement of CYP expression and
CYP3A4 activity and its functionality has since been confirmed in experiments examining
bioactivation and metabolism of cytotoxic drugs (Ma et al. 2012).
5.1.3 Further studies on the stable C3A-NR cell lines (unpublished)
The expression and activity of different CYPs in hepatoma cell lines have been shown to
depend  also  on  culture  conditions,  such  as  media  formulation  or  different  cell  culture
matrices. The impact of few selected chemicals on CYP3A4 activity in wild type and
modified C3A cells was briefly studied. Dexamethasone (DEX) is an anti-inflammatory
steroidal drug, which has been shown to increase the CYP3A4 activity, via the induction of
glucocorticoid receptor (GR) and PXR, up to 5-fold in the BC2 cell line (Gómez-Lechón et al.
2001). Vitamin D3 (1,23-(OH)2-D3, VD3) is involved in the growth and differentiation of cells
in several tissues and it has been shown to increase the CYP activity mainly in intestinal cell
lines  (e.g. Caco-2) but also in HepG2 cells (Drocourt et al. 2002, Elizondo & Medina-Díaz
2003, Fan et al. 2009). Serum  is  commonly  used  in  cell  culture  as  a  source  of  different
hormones and growth factors needed for proliferation.
Table 9. The effects of different media modifications on CYP3A4 activity in wild type and
modified C3A cell lines.
Cell line Media modificationb
Controla 100nM DEX 100nM VD3 5% serum
C3A wt 3,5   
hCAR28 0,3   
hCAR1.8 2,1 ND  
hPXR7 3,7   
hPXR15 0,4   
aCYP3A4 activity (pmol HFC/h/mg prot), b = 1-2.5 -fold,  = 2.5-5 -fold,  = over 5 -fold, 
= less than 1-fold, culture time 7 days. DEX=dexamethasone, VD3=vitamin D3 (1,23-(OH)2-
D3), ND=not done.
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Large variation was observed between cell lines but in general, the addition of DEX or VD3
or the reduced serum concentration caused a notable increase in CYP3A4 activity in those
cell lines with lower basal activity (Table 9.). However, the overall effects on the tested
media formulations were modest in this study and the control values for CYP3A4 activity
were low compared to the previous results obtained from these cells (II). Further tests
using different concentrations or combinations of added chemicals as well as the use of
another analytical method (e.g. LC-MS) might provide more consistent and accurate results.
5.2 XENOSENSOR ASSAYS AND HUMAN CAR LIGANDS
The development of functional cell-based and other in vitro and in silico assays to study the
biology and function of hCAR and to find novel specific hCAR ligands have been subjects
of several studies. The main problems and limitations of the previously used assays as well
as the properties of the receptor have been discussed in the previous sections.
5.2.1 Optimization and validation of the xenosensor assays (III)
Various reporter assays employing different cell lines and receptor constructs have been
used to study the activation of xenosensors but often they have not been validated or
otherwise assessed for predictivity or reproducibility. The Z’ factor (Z’) and signal window
(SW) parameters adjust the assay signal to the assay variability and can be used to evaluate
the overall quality or performance of an assay, and thus, in assay optimization and
validation (Iversen et al. 2006). Validation of assays is crucial; one needs to have both
reliable and reproducible prediction of the ability of a compound to activate a xenosensor
and  thus,  cause  induction  of  CYP  and  other  DMEs.  However,  the  validation  of  the  assay
does not guarantee an acceptable performance over time, so ongoing monitoring is
important.
The developed screening assays in the C3A cell line (III) fulfilled the acceptance criteria
parameters in repeated experiments, although the Z’ value for the AhR assay was slightly
under the acceptance level for an excellent assay (Table 10.). Compared to the assays used
by others, our hCAR (isoform 1) assay meets the acceptance criteria of an excellent assay
(both Z' and SW). The use of assays which do not fulfill these acceptance criteria, suggest
that at least some studies on hCAR activators have been performed in sub-optimal
conditions and thus, may have provided inaccurate predictions. The most important aspect
for the developed hCAR assay is that the basal activity of the receptor in C3A cells is
relatively low and the assay is able to identify also weak agonists without artificial
suppression  of  the  activity  by  the  use  of  inhibitors  (e.g. EE2, Jyrkkärinne et al. 2005),
artificial mutations on the LBD or the use of splicing variants (DeKeyser et al. 2009, Chen et
al. 2010c). Thus, our assay provides reliable information on the hCAR ligand binding
specificity and affinity. The low basal activity of hCAR in this cell line could be due to the
cofactor  content  (low  SRC1/TIF2  and  high  PGC1, Section 5.1) (Liu et al. 2002). In assays
which use an inhibitor to lower the basal activity, competition between the inverse agonist
and agonist may lead to misclassification of weak affinity ligands or partial agonists. The
hCAR.3 isoform has  been proposed to  be  a  suitable  tool  for  prediction of  hCAR.1  ligands
due to their similar ligand-binding properties and the low basal activity of hCAR.3
(Auerbach et al. 2005, Faucette et al. 2007). The hCAR.3 assays in general fulfill the
requirements of an excellent assay, while this is often not the case for the hCAR.1 assays
(Table 10.). However, the variants or mutations may affect the structure of the LBD and
ligand specificity of the receptor.
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Table 10. Examples of xenosensor reporter assays and their performance parameters.
Receptora Reference
compoundb
Cell line Performance
parametersc
References
(μM) Z' SW
hCAR (LBD)
hCAR (FL)
hCAR (FL)
hCAR.3 (FL)
hCAR (FL)
hCAR.3 (FL)
hCAR (FL)
hCAR.2 (FL)
hCAR.3 (FL)
hCAR (LBD)
hCAR (LBD)
FL81(10)
CITCO(0.25)
CLOTR(10)
CLOTR(10)
CITCO(1)
CITCO(1)
CITCO(5)
CITCO(5)
CITCO(5)
CLOTR(2)
TMPP(10)
C3A
HepG2
Huh7
Huh7
HepG2
HepG2
COS-1d
COS-1
COS-1
HEK293
HEK293
0.70
0.10
<0
0.86
< 0
0.55
< 0
< 0
0.60
0.79
0.40
7.8
< 1
<1
21
< 1
6.0
< 1
< 1
4.5
<1
4.4
III
Yao et al. 2011
Anderson et al. 2011
Anderson et al. 2011
Li et al. 2010
Li et al. 2010
DeKeyser et al. 2009
DeKeyser et al. 2009
DeKeyser et al. 2009
Jyrkkärinne et al. 2005
Jyrkkärinne et al. 2005
hPXR (LBD)
hPXR (FL)
hPXR (FL)
hPXR (FL)
hPXR (FL)
hPXR (FL)
hPXR (FL)
RIF(10)
RIF(25)
RIF(10)
RIF(10)
RIF(10)
RIF(10)
RIF(10)
C3A
Huh7
HepG2
DPX2d
HepG2
HepG2/hPXRd
C3A
0.59
0.40
0.56
0.77
0.87
0.52
0.70
4.7
3.0
4.2
10
28
3.4
7.3
III
Anderson et al. 2011
Li et al. 2010
Trubetskoy et al. 2005
Lemaire et al. 2004
Lemaire et al. 2004
Luo et al. 2002
hAhR (EG)
hAhR (EG)
hAhR (EG)
hAhR (EG)
hAhR (EG)
hAhR (EG)
hAhR (EG)
OME(10)
TCDD(5)*
OME(100)
3MC(1)
TCDD(10)*
3MC(2)
TCDD(10)*
C3A
AZ-AHRd
HepG2-A10d
HepG2-A10d
DRE1A2d
DRE1A2d
TV101L-CALUXd
0.48
0.82
0.20
0.68
0.97
0.87
0.45
4.3
9.6
< 1
6.6
160
23
1.9
III
Novotna et al. 2011
Sekimoto et al. 2007
Sekimoto et al. 2007
Yueh et al. 2005
Yueh et al. 2005
Long et al. 2003
Acceptance criteria
Iversen et al. 2006
Ideal
Excellent
Do-able
Yes/No
Unacceptable
Z’ = 1
Z' > 0.5
0 < Z' <0.5
Z' = 0
Z' < 0
Recommended
Acceptable
Unacceptable
SW > 2
SW > 1
SW < 1
The Z’ and SW values fulfilling the acceptance criteria for an excellent or recommended assay
are marked in bold. aLBD=ligand binding domain (fused with yeast GAL4-DNA binding domain),
FL=full length receptor, EG=endogenously expressed, bCLOTR=clotrimazole, 3MC=3-
methylcholanthrene ,*nM concentration cPerformance parameters are calculated based on the
activation data presented in the respective publications. dDPX2=HepG2 derivate harboring hPXR
and CYP3A4-promoter driven luciferase reporter (PuraCyp, Carlsbad, CA), AZ-AHR=HepG2
based cell line containing a luciferase reporter with several upstream AhR binding sites,
CALUX=chemical  activated  luciferase  expression  assay  (Murk  et  al.  1996),  DRE1A2=human
hepatoma cells harboring a DRE driven luciferase reporter (PuraCyp, Carlsbad, CA).
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In general, the hPXR and hAhR assays mostly fulfill, whereas most of the hCAR assays do
not, the acceptance criteria as judged by the calculated performance parameters (Table 10.).
In the present experiments, the hPXR and hAhR assays are also more reproducible in
repeated experiments than the hCAR assay, despite their lower Z' and SW values
(unpublished observation). The hCAR assay is in general more prone to variation; this may
be due to transfection efficiency or perhaps to the condition of the cells. Most of the hPXR
assays use a full-length receptor in comparison to the present assay which uses only the
receptor LBD. The pros and cons of the use of a full length receptor and the LBD have been
discussed in Section 2.3.3.
The hAhR assays are usually based on the use of endogenously expressed AhR and a stably
transfected luciferase reporter. In contrast, in the present assay, the reporter is transiently
transfected, which might affect the reproducibility of the results. The use of omeprazole as
a positive control has also been questioned due to its hPXR activation and CYP3A4
induction potential in comparison to beta-naphthoflavone (BNF) (Faucette et al. 2006,
Abadie-Viollon et al. 2010). In the present assay, BNF produced similar or higher reporter
activities than omeprazole but the results were highly variable between experiments
possibly due to compound instability (unpublished observation). In addition, since TCDD
is extremely toxic and thus difficult to use, omeprazole was chosen as a positive control for
the hAhR assay.
The validated assays can be used to assess the receptor transactivation by various ligands
and thus,  predict  the  possible  CYP induction caused,  but  as  such,  they cannot  necessarily
predict the overall effects caused by the chemical in vivo. A transient transfection assay is in
general laborious and also prone to errors, so to be used as high thoughput screening
methods for large amounts of ligands, the developed assays should be scaled to at least 96-
well format e.g. with the possibility to use a reverse transfection method (Reinisalo et al.
2006).
5.2.2 The search for novel hCAR ligands (I, III, IV)
Possibly due to the promiscuous nature and the ligand independent or indirect activation
of  hCAR  as  well  as  due  to  the  lack  of  reliable  and  predictive  assays,  only  a  few  selective
ligands for the receptor are known. Most of the studies used to find and study hCAR
activators have relied on different reporter assays; in particular, the selectivity of the
ligands over other xenosensors has not been studied (Poso & Honkakoski 2006). For
example, perhaps the reason why ambiguous results have been reported for clotrimazole
and meclizine is due to the different assays used in the studies (see below). Many studies
have also focused mainly on the basal activity or the activation mechanisms of hCAR and
not on identifying novel ligands. One aim of this work was to discover novel hCAR
agonists and inverse agonists and to study their selectivity, by using the above-mentioned
xenosensor assays together with other in vitro and in silico methods. A total of nearly 400
xenosensor activators or CYP inducers, selected based on virtual screening procedures (I,
IV) and literature (III, IV), were studied.
Agonists. Based on the M1H assay, CITCO, FL81 and permethrin (pyrethroid) (III) are
strong hCAR activators, while o,p’-DDT  (organochlorine,  minor  isomer  in  technical  grade
DDT) (III) and the substituted sulfonamides (3 and 6) (I) and thiazolidin-4-one derivatives
(9 and 14) are moderate hCAR activators (I) (Table 11., Figure 9.). The strong activators are
not specific for hCAR since they show at least moderate activation of hPXR (FL81) or hAhR
(CITCO and permethrin). Except for o,p-DDT, which is specific activator of hCAR at
concentrations below 3 μM, the moderate activators are also strong activators of hPXR (all)
and hAhR (9) (Table 11.). TMPP and TPP have been used previously as positive controls in
hCAR assays (Jyrkkärinne et al. 2005, 2008) and they produce fairly modest, although
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reproducible,  activation  of  hCAR.  However,  TPP  is  a  strong  hPXR  activator  and,  both
compounds are moderate activators of hAhR (Table 11.). All agonists evoked a robust
recruitment of SRC1, although a decrease in reporter activity was seen with high
concentrations (30μM) of CITCO, permethrin and o,p’-DDT, which was not due to toxicity
(Table 11.). None of the agonists showed any significant NCoR recruitment. In the LPD
assays,  the  unliganded  hCAR  LBD  was  degraded  by  subtilisin  A,  while  the  binding  of
different agonists provided protection to various degrees from proteolysis, supporting
direct association of the established agonists (CITCO, o,p'-DDT, permethrin and FL81) with
the hCAR LBD and further  hinting at  different  binding orientations  of  the  ligands within
the LBP.
While CITCO showed a strong induction of both CYP2B6 mRNA and activity, the increase
of CYP2B6 mRNA expression by other strong activators was very modest, although
selective for CYP2B6 over CYP3A4. However, permethrin showed a moderate induction of
CYP2B6 activity. Of the moderate activators, compound 14 (I) evoked a significant
induction of CYP2B6 mRNA and was selective over CYP3A4, while o,p'-DDT (III) was the
only chemical found to increase both CYP2B6 and CYP3A4 as well as CYP1A2 mRNA
expression, even though it did not activate hAhR in the M1H assay (Table 11.). This is
probably due to the PXR and CAR-mediated regulation of CYP1A2 expression (Maglich et
al. 2002).
Although the established hCAR agonist CITCO (Maglich et al. 2003) has been used as a
positive control for hCAR activation in many reporter gene assays (Table 10, I), its
activation potential varies significantly between and within studies, possibly due to its poor
stability (Jyrkkärinne et al. 2008, Dring et al. 2010). CITCO also fails to show a dose-
dependent increase in hCAR activity, cofactor recruitment and CYP induction, at least with
over 100nM concentrations. Many pesticides of various chemical classes have been shown
to induce CYP expression and recently the developed hCAR assay (Section 5.2.1) was used
to study different pesticides for their hCAR activation (Abass et al. 2012). Together with
permethrin and o,p´-DDT,  these  newly  found  chemicals,  in  addition  to  FL81  and
compounds 3, 6, 9 and 14, represent novel chemical types of hCAR ligands.
Inverse agonists. All of the established inverse agonists evoked a decrease in hCAR activity
(10-77 %) in the M1H assay (Table 11., Figure 9.). Both PK11195 and S07662 were strong
hPXR and weak hAhR activators. In contrast, neither EE2 nor androstenol activated hPXR
and they even decreased the activity of AhR (50-80%, unpublished results). The SRC1
recruitment was low for all other inverse agonists, except for PK11195, suggesting that the
compound might in fact be a partial agonist of hCAR. A strong NCoR recruitment was
observed only with S07662 and PK11195, while the results were very modest for both EE2
and androstenol. However, in the Y2H assay, the hCAR/NCoR interaction was strongly
induced  by  all  of  the  inverse  agonists,  as  well  as  by  another  steroidal  compound,
etiocholanolone (data not shown). The interactions with cofactors could be blocked via
competition with agonists in both SRC1 and NCoR interaction assays (IV, unpublished
results). Similarly to the situation with the agonists, the strong inverse agonists protected
the LBD from digestion better than the weaker inverse agonist EE2 in the LPD assay.
Furthermore,  all  inverse  agonists  suppressed  the  induction  of  CYP2B6  mRNA  by  CITCO
and phenytoin. In the absence of agonists, CYP2B6 mRNA was induced moderately by the
three  other  inverse  agonists;  in  contrast,  S07662  caused  only  a  very  modest  induction.
CYP3A4 mRNA was induced moderately (up to 7-fold) by both S07662 and PK11195,
whereas the steroidal inverse agonists showed no effect. Despite some drawbacks, such as
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the  lesser  degree  of  suppression  of  CITCO-mediated  CYP2B6  induction  and  hPXR
activation, S07662 represents a novel useful tool for studies of hCAR biology.
Figure 9. Chemical structures of A) agonists, B) inverse agonists and C) the problem children.
Problem children. The  antifungal  clotrimazole  has  been  reported  to  act  both  as  a  modest
agonist (Jyrkkärinne et al. 2005, Dring et al. 2010) and inverse agonist (Moore et al. 2000 and
2002,  Auerbach  et  al.  2003)  for  hCAR.  In  this  study,  clotrimazole  displayed  a  modest
activation of hCAR (M1H), relatively high SRC1 and low NCoR recruitment at the sub-toxic
concentrations (Table 11., Figure 9.). Meclizine is a histamine H1 receptor antagonist,
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reported to act as an inverse agonist at human CAR, based on the decrease in the
hCAR/SRC1-interaction at 20μM as well as the decrease of PB-induced CYP expression
(Huang et al. 2004). In this study, meclizine exhibited a modest hCAR activation (M1H) as
well as SRC1 and NCoR recruitment (M2H) (Table 11., Figure 9.); similar observations have
also been reported by others (Lau et al. 2011). These results suggest that meclizine is not an
inverse agonist of human CAR.
Two anticonvulsant and antiepileptic drugs, phenobarbital (PB) and phenytoin (PHN), are
both established CYP2B6 inducers via activation of CAR and PXR (Figure 9., Kawamoto et
al. 1999, Rushmore & Kong 2002, Wang et al.  2004). Both of the compounds were inactive
in the hCAR reporter assay but PB activated hPXR as reported earlier (Table 11., Luo et al.
2002). However, PHN, and to a lesser extent also PB, were able to recruit SRC1 in the M2H
assay dose-dependently, to protect the LBD from degradation and the degree of protection
correlated with the extent of SRC1 recruitment. This finding suggests that the alleged
indirect activation mechanism of hCAR by different phosphorylation events leading to
nuclear  translocation  could  in  fact  be  a  consequence  of  the  binding  of  a  weak  ligand  for
which the hCAR activation cannot be shown in conventional reporter assays. As expected,
both compounds induced CYP2B6 and CYP3A4 mRNAs but had different selectivities, PB
favoring CYP3A4 (probably due to hPXR activation), while PHN was clearly more selective
for CYP2B6.
Comparison of ligand binding modes. The size of the hCAR LBP allows ligand binding in
different orientations and even though the established ligands possess moieties capable of
hydrogen bond formation, the hydrophobicity of the pocket encourages binding mainly via
van der Waals interactions. Since no clear interaction points (e.g. H bond donors or
acceptors) can be found in the LBP, it  is difficult to define any specific chemical groups or
structures that an agonist or inverse agonist should possess in order to bind and/or alter the
activation of the receptor. Thus, the identification of interaction areas or amino acid side-
chains important for ligand binding would be beneficial for determining the required
properties of a ligand. Previous docking and mutation studies have found different
coefficient regions (positive I-III and negative IV) and subpockets (S1 and S2), important for
ligand binding and hCAR activation (Jyrkkärinne et al. 2008, Figure 10.). The subsite S1,
overlapping with coefficient region I, is targeted by compounds that activate hCAR
efficaciously. The channel C1, with a negative coefficient region IV at the end, connects the
LBP with H12 (Jyrkkärinne et al. 2008, Figure 10.). Occupation of this region may result in
steric clashes and displace the H12 from its active conformation, thus preventing
coactivator interaction, or conversely, it may promote interactions with corepressors. The
amino acid residues F161 (H3), N165 (H3), F234 (H6/H7 loop) and Y326 (H11) form a so-
called LBD/H12 interface, creating a barrier between the H12 and the LBP, and this
prohibits any direct contacts of ligands with H12 (Xu et al. 2004, Jyrkkärinne et al. 2008,
Figure 10.).
In this study, selected compounds were docked into the hCAR crystal structure (PDB entry
1XVP9, chain D) using two versions of the GOLD docking suite. In studies III and IV, the
side chains F161 and Y224 were allowed to move freely ("flexible docking"), whereas in
study I, all the side chains were “rigid”. In study I, two different binding modes were
observed. Compounds 3 and 9 were shown to bind deep in the LBP in a compact
conformation and interact with the small hydrophobic subsites (S1 and S2, Figure 10.)
within the LBP. In contrast, compounds 6 and 14 adopted a more stretched L-shaped
conformation and were bound to the channel which connects the LBP with H12 (C1, Figure
10.). However, as the earlier studies, as well as study I, have been based on a limited
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number  of  chemicals  or  chemical  groups  and  on  the  "rigid"  docking  procedure,  the
predictions may differ from those obtained with flexible docking. Based on the results from
MD simulations (III, IV),  both the  C-terminal  end of  hCAR (harboring HX and H12)  and
the H2/H3 loop were stabilized and destabilized in different ways by different ligands. As
described in Section 2.2.1, both H3 and HX may be involved in retaining H12 in the active
position and contribute to the high constitutive activity. The H2/H3 loop is thought to be
one of the ligand entry sites (Martinez et al. 2005).
Strong agonists  CITCO and FL81,  and to  some extent  also  permethrin,  stabilized HX and
H12 in the active position. Permethrin appeared to stabilize the H2/H3 loop better than the
other ligands. The poorest stabilization of the loop was observed with FL81 and this might
explain the lower SRC1 recruitment. However, the recruitment of other coactivators by
FL81 (or any of the other ligands) was not studied in this work, and thus this result may not
be conclusive. Nonetheless, these contrasting results show that different strong agonists can
exhibit very different stabilizing effects on the LBP, all of which can lead to the activation of
the receptor. Weaker agonists, such as clotrimazole and PHN, seem to push H12 towards
H10  unfavourably  for  coactivator  binding  and  only  stabilize  the  C-terminal  part  of  the
H2/H3 loop.
Figure 10. Schematic presentation of features of the hCAR LBP important for ligand binding and
hCAR activity (adapted from Xu et al. 2004). A) Barrier residues, important helices and loops.
The LBP is presented in dark grey. B) The approximate locations of positive coefficient region I,
subsite S1 (framed by H2', H6 and 3 strand), the negative coefficient region IV and channel
C1, connecting the LBP and H12, are presented as light gray circles (Jyrkkärinne et al. 2008).
Positive  coefficient  regions  II  and  III,  as  well  as  helices  6  and  7  (A)  have  been  omitted  for
clarity.
Reporter  assays  with  selected  alanine  mutants  revealed  that  the  mutation  of  Y326,  which
plays  a  central  role  in  stabilizing  H12  and  also  in  the  constitutive  activity  of  hCAR,
abolished or reduced (50% or more) hCAR activation by the agonists tested. In contrast,
mutation of  N165,  which forms a  hydrogen bond with Y326,  resulted in  the  enhancement
(e.g. CITCO,  FL81,  TPP,  clotrimazole)  or  reduction  (o,p'-DDT) of hCAR activity, while
permethrin  caused  only  negligible  effects.   F161  and  F234  are  central  amino  acids  in  the
ligand-dependent activation of hCAR (Jyrkkärinne et al. 2008). Clotrimazole was the only
compound  able  to  activate  the  F161A,  possibly  due  to  its  rigid  structure  and  its  central
position in the pocket. In contrast, all agonists were able to activate the F234A mutant and
the activity was enhanced in comparison to the activation of the wild type receptor
obtained by treatment with CITCO, o,p’-DTT, clotrimazole and permethrin.
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Collectively, the hCAR agonists occupy distinct but partly overlapping regions of the LBP
and are able to increase its volume. Based on the accumulation of structurally variable
hCAR  ligands  (e.g. Figure 9.),  the  LBP  is  most  likely  rather  flexible  and  interactions  with
certain residues are able to reshape the binding cavity.
The inverse agonists also seem to stabilize the LBP, especially around the H2/H3 loop, but
in  comparison  to  the  agonists,  the  LBP  is  opened  more  in  the  direction  of  H12.  The  two
strong inverse agonists, S07662 and PK11195, both affect the position of H12: While the
effect of S07662 is more direct, PK11195 seems to influence the conformation HX by
affecting the H6/H7 loop. In contrast to CITCO, neither of these inverse agonists increased
the helical content of HX. Due to its larger size and Y-shaped structure, PK1195 may occupy
and interact with the LBP more effectively than for example the smaller and L-shaped
S07662, and this might be connected to its possible partial agonism (see above, Figure 9.).
Although the present data and the results from further studies (see below, Jyrkkärinne et al.
2012) suggest some features and mechanisms connected with inverse agonism, in part due
to the fact that no hCAR crystal structure with bound inverse agonist and corepressor is
available, the exact mechanism of inverse agonism for CAR remains unclear.
Comparison and limitations of different assays. The M2H assay is more sensitive in
detecting weak hCAR agonists than the M1H assay (approx. 11-fold difference), since most
of the compounds showed increased reporter activity at low (< 1μM) concentrations. In
general, the results from M1H and M2H correlate fairly well. The drawback of the M2H
assay, and also one possible explanation for the discrepancies between the M1H and M2H
results, is that only one coactivator is included in the assay, whereas several cellular
coactivators are present in the M1H assay. Thus, the choice of cell line for M1H assays is of
great importance since the activation of NRs or AhR depend on the cofactor content of the
cells being used. As mentioned in Section 5.2.1, the cofactor content may play a role in the
low basal activity of hCAR encountered in the C3A-based M1H assay. Similarly,
competition for the recruitment of NCoR could be one of the explanations for the low
corepressor recruitment by EE2 and androstenol in M2H, whereas in Y2H, both of these
ligands induce a strong hCAR/NCoR interaction. There may be other explanations, such as
differential transport or metabolism of these ligands or differences in the post-translational
modification of the coregulator peptides. Furthermore, since both EE2 and androstenol
decrease the activity of the endogenous AhR, these compounds may act through some
unknown pathways or processes in C3A cells, resulting in the low hCAR/NCoR interaction.
In general, even though good correlation between reporter assays and CYP expression for
hPXR and hAhR has been shown (Luo et al. 2002, Sugihara et al. 2008) direct comparisons
between  these  two  methods  are  problematic.  The  poor  correlation,  seen  for  hCAR  and
CYP2B6/3A4, may result from several factors: 1) The differential DT expression profiles of
hepatoma cells and primary hepatocytes could lead to differences in the intracellular levels
of the compounds (Teng et al. 2003), 2) the coregulator specificity of the receptor may
depend on which ligand is bound as well as the coregulator profile of the cells, 3) the test
compounds may be differentially metabolized in hepatoma cells and primary hepatocytes
and 4) the test compounds may inhibit the measured CYP enzymes in primary hepatocytes.
Compounds 3 and 6 contain ester groups, which can be easily hydrolyzed in hepatocytes,
in contrast to the non-ester compounds 9 and 14 (I). FL81 and permethrin are also
metabolized in HLMs but the specific metabolizing enzymes or metabolites have not been
identified (unpublished results). Most of the compounds tested in study I contain chiral
centers and since racemic mixtures were used in the assays, neither the isoform specificities
in hCAR activation nor the possible metabolism in hepatocytes are known. Similarly, trans-
permethrin has previously been shown to be metabolized by esterases both in vivo and in
vitro (Takaku et al. 2011). Preliminary inhibition studies revealed that several of the hCAR
activators were inhibitors of CYP2B6 and some CYP3A4 inhibition was also observed, with
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permethrin and FL81 showing especially strong concentration-dependent CYP3A4
inhibition and a moderate inhibition of CYP2B6 with the recombinant enzymes.
The LPD assay, measuring increased protection of the NR from degradation due to ligand
binding in vitro, can be used to study the association of ligands with the hCAR LBD. Even
though no specific protected fragment can be associated with agonists or inverse agonists,
the  presence  of  different  fragments  with  different  ligands  suggests  that  the  ligands  have
different binding orientations within the LBP.
The initial pharmacophore search in study I limited the structural variability of the
resulting database subset, which is evident by all of the identified compounds belonging to
two  distinct  chemical  classes.  Furthermore,  the  lack  of  flexibility  in  the  first  docking
approaches (e.g. Windshügel et al. 2007, I), the lack of coregulator peptide (I, III, IV) and
the short length of the MD simulations (III, IV) at least partly made it difficult to identify
the distinguishing features of agonists and inverse agonists in silico (Windshügel  &  Poso
2011, Jyrkkärinne et al. 2012). In later simulations, which contained also the SMRT peptide,
it was shown that the effects of agonists on the H2-H3 loop were very modest, whereas the
inverse agonists tended to destabilize the loop (Jyrkkärinne et al. 2012). In addition, the
stabilization and orientation of H12 (moves towards H10 with inverse agonists) and HX
(less stable with inverse agonists) differed between agonists and inverse agonists. In
addition, the changes elicited by the inverse agonists were subtle perhaps due to the lack of
the  corepressor  peptide  in  the  simulation.  The  subsequent  study  showed  that  the  inverse
agonists caused a clearer shift of H12 when the SMRT corepressor peptide was included in
the MD simulations (Jyrkkärinne et al. 2012). The ligand binding as such also induced large
movements in the protein, not only reshaping and increasing the volume of the LBP but
also evoking allosteric effects and thus, at least docking studies alone are not sufficient to
define the activation or inactivation of the receptor seen after incubation with specific
compounds.
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6 Conclusions and future prospects
The following conclusions can be drawn from this study:
1. The results from study II demonstrate the proof of principle that the expression of
multiple CYPs can be simultaneously upregulated by the constitutively active
chimeric CAR and PXR, in hepatoma cells. A similar approach could be used for
other cell lines lacking expression or function of the genes involved in xenobiotic
metabolism. One of the established cell lines, hCAR28, has also been shown to
exhibit higher CYP3A4 activity than the parent cell line (Ma et al. 2012). The
obtained cell lines, especially the subline hCAR28, could be used in studies modeling
the  interindividual  differences  in  CYP  activities.  However,  further  studies  will  be
needed to determine the impact of culture conditions on DME expression in these
cells.
2. The optimized and validated xenosensor assays provide a robust and reproducible
method for screening potential xenosensor ligands and, together with other methods,
predict the possible CYP induction resulting from the activation of the xenosensors.
The hCAR assay is the first protocol which does not require the addition of
supplemental chemicals or mutations to decrease the high basal activity of CAR and
thus,  can  provide  reliable  information  on  the  hCAR  ligand  binding  specificity  and
affinity. The assays enable the use of different receptors to study the ligand
specificities between xenosensors and other NRs or to compare the responses to
ligands between different  species.  The sensitive  M2H assay can be  used to  identify
and to study the properties of weak hCAR ligands. In this study, only two cofactors
(SRC1  and  NCoR)  and  one  NR  (hCAR)  were  used  but  different  NRs  and  cofactors
could be cloned into respective vectors to make the assay more versatile and to study
the cofactor specificity of different receptors.
3. The established novel hCAR ligands, FL81 and S07662, are suitable and stable
reference compounds for different reporter assays, although they do not perform
equally  well  in  CYP  mRNA  expression  studies.  Together  with  other  established
hCAR ligands from novel  chemical  classes,  they can also  serve as  lead compounds
for the generation of new ligands for research and for the development of new
selective compounds targeting hCAR. In general, this study highlights the problems
encountered in evaluating specific xenosensor, especially hCAR, ligands. Thorough
analyses are required before any novel chemical entity can be used as a reference or
a lead compound.
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Three xenosensors, constitutive an-
drostane receptor (CAR), pregnane X 
receptor (PXR) and aryl hydrocarbon 
receptor (AhR), are main regulators 
of enzymes and transporters impor-
tant for xenobiotic metabolism and 
disposition. In this thesis, modified 
xenosensors were used to increase 
the cytochrome P450 (CYP) expres-
sion in hepatoma cells. Xenosensor 
reporter assays were validated and 
used together with other biological 
assays and molecular modeling tech-
niques to find ligands and to study 
the function of human CAR. Novel 
hCAR ligands are presented and their 
properties are compared to previously 
described compounds. 
